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UGUUUC-3’ which facilitated AAV2 transduction. Chemical compound enhancers included ellagic acid,
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to understand a mechanistic basis for them through studies which individually quantified enhancement at
stages including the virus-receptor interaction, the viral DNA introduction into the cell, reporter gene RNA
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compounds which enhance transduction can lead to a better understanding of AAV2 biology and may provide
a foundation for the engineering of novel AAV formulations, delivery systems, or vectors.
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ABSTRACT 
HIGH THROUGHPUT SCREENING FOR THE ENHANCEMENT OF ADENO-
ASSOCIATED VIRUS TYPE 2 TRANSDUCTION 
Alexis Jessica Wallen 
Dr. Scott L. Diamond 
Adeno-associated virus (AAV) is a promising vector for human gene therapy.  Although 
more effective than non-viral vectors, AAV still requires improvement in efficacy in 
order to become a successful gene therapy vector.  With this in mind, we have sought to 
identify and examine identified enhancers of adeno-associated virus type 2 (AAV2) 
transduction.  Using a high throughput screening system with recombinant AAV2 
carrying the luciferase reporter gene (AAV2-Luc), we found siRNA sequences and 
chemical compounds which increase AAV2 reporter gene expression.  We specifically 
identified a hexamer seed region 5’-UGUUUC-3’ which facilitated AAV2 transduction.  
Chemical compound enhancers included ellagic acid, 1,10-phenanthroline, EGFR 
tyrosine kinase inhibitors, nucleoside analogs, and DNA alkylating agents.  Although 
several of these compounds, such as EGFR tyrosine kinase inhibitors and DNA 
alkylating agents, were known enhancers of AAV transduction, compounds such as 
ellagic acid and 1,10-phenanthroline were newly identified as facilitating AAV2 
transduction.  After identifying these enhancers, we have further sought to understand a 
mechanistic basis for them through studies which individually quantified enhancement at 
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stages including the virus-receptor interaction, the viral DNA introduction into the cell, 
reporter gene RNA transcription, and the production of protein from the transgene.  The 
identification of siRNAs and chemical compounds which enhance transduction can lead 
to a better understanding of AAV2 biology and may provide a foundation for the 
engineering of novel AAV formulations, delivery systems, or vectors. 
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Chapter 1 
1. Introduction 
Modern medicine has led to major advances in the prevention and treatment of human 
diseases.  Drugs and biotechnology products are available to treat a variety of ailments. 
Antibiotics serve as an effective cure for bacterial infections, many pills can treat disease 
by blocking or promoting a particular biological pathway, vaccines can prevent infection, 
and monoclonal antibodies can treat cancer as well as other diseases.  However, many 
illnesses still cannot be adequately addressed with existing medications.  Gene therapy, 
the use of nucleic acids to prevent or treat a disease, is a novel approach that holds 
promise for treating many of these conditions.  Either ribonucleic acid (RNA) or 
deoxyribonucleic acid (DNA) are introduced using either a non-viral or viral delivery 
vehicle, called a vector.  Although non-viral methods have many advantages, including a 
low risk of pathogenicity, non-viral methods have thus far failed to show adequate 
transgene expression for therapeutic benefit.  Viral gene therapy methods hold great 
potential, however, further research is required to develop a safe and effective gene 
therapy vector.  In this work, we will focus on high throughput screening for enhancers of 
adeno-associated virus type 2 (AAV2), a promising vector for viral-mediated gene 
delivery. 
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1.1. Non-viral Gene Therapy 
Traditional non-viral methods of gene therapy include injection of “naked” plasmid DNA 
or of a formulation which packages the DNA.   In the first case, plasmid DNA is injected 
directly.  In the second case, plasmid DNA is formulated with either a lipid or polymer.  
In a cationic lipid system, the positively charged lipid associates with the negatively 
charged DNA.  This both condenses the DNA and shields the negative charge from the 
cell’s lipid bilayer membrane, facilitating transport of the DNA into the cell.  A similar 
system can be formulated using polymers which mimic lipids, but which allow special 
engineering and targeting of the system
1, 2
.  Variations on these systems include the use 
of electroporation, gold nanoparticles, or ultrasound to enhance delivery
3
. 
Although these systems are considered safer than viral methods, there is potential for the 
non-viral carrier to elicit an immune response to both the carrier as well as to the 
transgene.  Care must be taken in the design of such as system in order to minimize an 
immune system response. 
While non-viral gene delivery does have several characteristics making it desirable for 
gene therapy applications, it has thus far been limited by low transgene expression.  The 
main application of plasmid DNA for gene therapy has been the development of 
vaccines, which require only a small amount of antigen to be expressed in order for the 
immune system to respond. However, even DNA vaccines have shown limited success
4, 5
. 
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1.2. Viral Gene Therapy 
Viral gene therapy has the advantage of being more efficient than non-viral gene therapy.  
Viruses have evolved over time to be highly capable of transducing human cells, and the 
wide variety of virus strains allows researchers a large toolbox of characteristics from 
which to choose.  Some viruses are specific to certain types of tissue or to dividing or 
non-dividing cell types.  Viruses can be selected that do or do not integrate into the 
genome.   
While it is helpful to have so many different viruses from which to choose, most viral 
methods of gene delivery do present a safety concern, especially given the clinical history 
of treatments with retroviruses and adenovirus.  In the case of retrovirus, the gene therapy 
succeeded in curing X-linked severe combined immunodeficiency (X-linked SCID), but 
several of the patients developed leukemia
6-9
.  In the case of adenovirus, a 1999 clinical 
trial for the liver-directed gene therapy treatment of ornithine transcarbamylase 
deficiency led to the immune-response linked death of a patient
10, 11
.  Although these 
trials showed promise for efficacy of human gene therapy, it was clear that the 
development of a safer vector was needed.  Adeno-associated virus (AAV) is seen as a 
promising viral vector for gene delivery with a strong safety profile.   
1.3. Adeno-associated Virus as a Gene Therapy Vector 
AAV, although widespread in the population, has not been known to cause any human 
disease.  This small virus, with a diameter of 20 nm packaging 4.7 kb of single-stranded 
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DNA, was originally discovered as a contaminant in an adenovirus preparation and is 
incapable of replicating in the absence of a helper virus
12
. The engineered virus 
additionally has all replication genes removed, so replication does not proceed even if a 
helper virus is present.  The wild-type virus integrates into the human genome at a 
specific location on chromosome 19 which has not been implicated in oncogenesis 
13, 14
. 
The engineered virus does not integrate into the genome due to the missing Rep gene 
which facilitates integration 
15, 16
.  In general, the low immune response and lack of 
associated human disease make it a strong candidate for viral gene therapy.  The virus 
additionally exists in nature in a variety of serotypes, which show differences in tropism 
for various target organs within the human body.  
Adeno-associated virus does, however, have some disadvantages as a vector.  Because 
the engineered virus lacks the ability to insert into the chromosome, gene expression will 
be lost over time in dividing cell types.  Additionally, thus far success in clinical trials has 
been elusive due to limited transgene expression.  In laboratory experiments, previous 
researchers have found a range of anywhere from 1 in 100 to 1 in 10
6
 viral particles will 
succeed in transducing cells, depending upon the cell line and conditions used 
17-19
. 
However, strong advances are being made in increasing transduction efficiency through 
directed evolution of virus and targeted virus mutations. 
1.4. Adeno-associated Virus type 2 biology 
In this work, we have chosen to focus on adeno-associated virus type 2 (AAV2), as it is 
the most well-characterized serotype.  The biological pathway for AAV viral entry and 
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gene expression contains numerous steps involving host proteins that control the level of 
transgene delivery and expression.  First, AAV must bind to heparin sulfate proteoglycan 
cell surface receptors 
20, 21
.  Following binding, AAV must be endocytosed in the 
presence of αVβ5 integrin and with activation of Rac-1 
21
.   Following endosome escape, 
the viral genome must gain entry to the nucleus, where viral DNA synthesis and 
transcription of the viral genome take place.   
 
Figure 1.1: Adeno-associated viral transduction.  Viral particles attach to cell surface 
receptors, are endocytosed via a clathrin-coated pit, escape from the endosome, are 
transported to the perinuclear space, cross the nuclear membrane, are uncoated, and the 
second strand of DNA is synthesized.  Once double-stranded DNA is in place, normal 
cellular machinery is used to transcribe DNA to RNA, which is then transported out of 
the nucleus, where RNA is translated to protein. 
In this work, we seek to add to the adeno-associated virus literature in an attempt to 
enhance adeno-associated virus transduction efficiency.  Although this virus has been 
extensively studied, there are still many unknowns in the viral transduction pathway.  
Here, we use two high throughput screens to better understand the virus, with the dual 
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goals of providing insight into the biology of the virus and providing new information to 
benefit future efforts to design better formulations and/or engineer next generation AAV 
serotypes.  
1.5. Pseudotyped AAV 
AAV exists in nature in a variety of serotypes which have slight differences.  For 
example, whereas type 2 binds to heparan sulfate proteoglycan, type 1 binds to sialic acid 
on the cell surface and type 9 binds to galactose on the cell surface 
22, 23
.  Coreceptors 
additionally facilitate the binding to these primary receptors.  A pseudotyped vector 
contains the capsid from one serotype and the genome from a different serotype, allowing 
independent manipulation of the viral capsids and genome 
24-26
. 
1.6. RNA Interference 
RNA interference is a naturally occurring process in which antisense RNA is used to 
generate a host cell response which leads to the degradation of the complementary 
RNA
27
.  siRNA, or short interfering RNA, is a short double-stranded RNA of 21-23 
nucleotides which effectively uses this cellular machinery to generate a strong knock-
down of RNA 
28
.  This knock-down of RNA leads to a decrease in corresponding protein, 
allowing loss-of-function experiments. 
Despite optimization of siRNA sequence selection, both sequence-dependent and 
sequence-independent off-target effects may occur, causing unintended effects 
29-36
.  For 
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example, an individual siRNA targeting a particular gene can show a different mRNA 
expression profile from another siRNA that successfully targets the same gene 
29
.  An 
additional type of sequence-dependent off-target effect arises from the hexamer seed 
region, located at positions 2-7 of the siRNA sequence.  This region can bind to the 
3’UTR of various mRNA species and can lead to a complex pattern of mRNA cleavage 
and translational silencing 
31, 33
, thereby functioning in a similar manner as microRNA 
(miRNA).   
In the first of two high throughput screens described in this work, we utilize this 
mechanism to identify siRNA enhancers of viral transduction. 
 
Figure 1.2: Mechanism of siRNA and miRNA pathway.  A) In the siRNA pathway, 
double-stranded siRNA is introduced into the cell, where it is recognized by and loaded 
into the RNA-induced silencing complex (RISC).  When complementary mRNA is 
found, the RNase is activated and cleaves the mRNA strand.  B) in the miRNA pathway, 
similar events occur, however the miRNA can be either perfectly complementary to the 
mRNA or complementary to only the hexamer seed region.  The result is either mRNA 
degradation or translational repression. 
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1.7. Chemical Modifiers of Viral Transduction 
As described in section 1.4, the interaction between viruses and host cells is complex.  
Chemical modifiers have the potential to interact with the virus or its products at each 
step of the viral transduction pathway and to activate or inhibit these stages.  In a second 
high throughput screen, we used small molecule chemical compounds known to be 
pharmacologically active in order to perturb this system and learn more about the cell-
virus interaction and enhancements of this interaction.  
1.8. Objectives 
The overarching goal of this work was identification of enhancers of AAV2 transduction, 
with the desired outcome of learning more about the AAV2 pathway and providing 
information that can lead to the engineering or formulation of a more effective AAV2 
vector.  In order to do so, we have conducted two high throughput screens.  In the first, 
we examined siRNA and were able to identify a consensus hexamer seed region.  In the 
second, we identified several chemical compound enhancers of AAV2, some previously 
known to enhance AAV2 and some which were newly identified. 
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Chapter 2 
2. siRNA High Throughput Screen 
The majority of this work has been published in Molecular Therapy.
37
 
Adeno-associated virus (AAV) is a promising vector for gene delivery.  AAV vectors 
have several advantages including: low pathogenicity, low immune response, long term 
episomal expression in nondividing cell types, and specific organ targeting based on the 
serotype used 
38-41
.  However, insufficient transgene expression has limited the success of 
a number of human clinical trials that used AAV vectors 
42-45
.  Although AAV vectors 
result in higher transduction than nonviral methods, a major goal is to increase the 
efficiency of gene transfer.  This cannot be simply overcome by continually increasing 
vector dosages, as higher doses are more likely to elicit an immune response and would 
present additional challenges to manufacturing capacity, cost of treatment, and/or 
treatment administration. 
Although the early steps of binding and endocytosis are well studied, many virus-host 
interactions remain unknown which may enhance or reduce viral transgene expression.  
The ability of knocking down individual targets makes siRNA extremely useful for high 
throughput screening.  A number of published studies have used this technique to 
examine virus/host cell interactions
46-52
, usually in the context of reducing viral infection 
(as opposed to enhancing transgene expression).   
10 
 
To help identify intracellular barriers to AAV transgene expression, we conducted a high 
throughput screen using short interfering RNA (siRNA) to knock-down mRNA 
corresponding to 5,520 Applied Biosystems “druggable genome” targets.   In the present 
study, off-target effects caused by a common seed region sequence were observed in 4 of 
the top 5 screening hits.  Also, mRNA profiling was used to investigate additional off-
target effects where a complex phenotype emerged involving downregulation of genes of 
the interferon pathway. 
2.1. Materials and Methods 
2.1.1.  Cell culture  
Human Aortic Endothelial Cells (HAEC; Lonza, Walkersville, MD) were cultured in 
supplemented Clonetics EGM-2 (Lonza, Walkersville, MD) at 37ºC and 5% CO2.  Prior 
to siRNA treatment, cells were rinsed with Dulbecco’s phosphate-buffered saline and 
incubated with 0.05% Trypsin-EDTA (Invitrogen, Santa Clara, CA), then seeded onto 96 
or 384 well flat bottom plates (BD Bioscience, Franklin Lakes, NJ).    Human bronchial 
epithelial cells (Lonza, Walkersville, MD) were grown in cell culture flasks containing 
supplemented bronchial epithelial growth media (BEGM) for 4-5 days at 37ºC and 5% 
CO2.  Human bronchial epithelial cells were then seeded at a density of 10
5
 per well onto 
96 well flat bottom plates (BD Bioscience, Franklin Lakes, NJ) and cultured in an equal 
mixture of bronchial epithelial basal media and Dulbecco’s modified Eagle’s medium 
11 
 
(Invitrogen, Santa Clara, CA).  Cells became confluent within 4 days and were allowed to 
grow for 2 weeks prior to forward transfection. 
2.1.2.  Druggable genome library  
The Druggable Genome Library (Applied Biosystems, Foster City, CA) was used for 
screening.  This library consists of 5,520 gene targets and 3 siRNAs per gene.  The 
library was provided in 384 well plates, each well containing 0.25 nmol of lyophilized 
siRNA.  The two columns on the right of the plate were left empty for controls.  Sterile 
nuclease-free water (Applied Biosystems, Foster City, CA) was added to each well in 
order to resuspend the siRNA at a concentration of 3125 nM.  Additional nuclease-free 
water was used to dilute the siRNA to a working concentration of 330 nM.  For the 
primary screen, the three siRNAs targeting the same gene were pooled together in equal 
quantities to create a pooled master.  The pooled master was then used to create assay 
plates containing 2 µL of siRNA, with each individual siRNA at a concentration of 110 
nM, for a total pooled siRNA concentration of 330 nM.  For the confirmatory screen, the 
desired individual siRNAs were aliquoted from the diluted master, and used to create 
assay plates containing 2 µL of siRNA, with each individual siRNA at a concentration of 
330 nM.  Seven columns on the right and left sides of each plate contained controls.  
Following the confirmatory screen, work was performed at larger scale (96 wells or less 
per plate), and in those cases the siRNA were ordered individually and resuspended using 
sterile nuclease-free water at a concentration of 3125 nM.   
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2.1.3.  Mutated siRNAs  
For examination of off-target effects resulting from the seed region of the siRNA 
sequences, three mutated siRNA sequences were designed in which individual point 
mutations were introduced into positions 1, 4, and 14, respectively, of the siRNA strand 
corresponding to Applied Biosystems siRNA 145736 (CLIC2 sequence C).  In each case, 
the siRNA sense strand was complementary to its mutated antisense strand.  The mutated 
siRNAs were chemically identical to the original Applied Biosystems Silencer siRNAs, 
with the exception of the point mutations, and sequences are given in Table 2.1. 
Gene 
Name  
siRNA 
ID#  
Letter 
Code  
Antisense Sequence  Primary 
Screen Fold 
Increase 
(pooled) 
Secondary 
Screen Fold 
Increase 
(single siRNA) 
SLC5A2  41847  B 5’-ACAGUGCCUCUGUUGGUUCtg-3’ 13.9  6.0  
ABCA8  117435  A 5’-UUGUUUCAUAACAAUGAGCtg-3’ 17.7  4.6  
CLIC2  145736  C 5’-AUGUUUCUAAGGAGCAGGGtg-3’ 16.9  4.3  
GPR124  34695  B 5’-AUGUUUAGUCGGAGAAGCCtg-3’ 7.0  3.4  
LCK  668  A 5’-AUGUUUCACCACCUCUCCCtg-3’ 22.1  3.4  
CLIC2(C)-A1U mutant  5’-UUGUUUCUAAGGAGCAGGGtg-3’   
CLIC2(C)-U4A mutant  5’-AUGAUUCUAAGGAGCAGGGtg-3’   
CLIC2(C)-G14C mutant  5’-AUGUUUCUAAGGACCAGGGtg-3’   
 
Table 2.1.   siRNA sequences providing the top hits in secondary screening of individual 
siRNAs, and point-mutated siRNA sequences based on CLIC2 sequence C.  The bases 
shared in the seed region between four of the five sequences are italicized.  The point 
mutations made to CLIC2 sequence C are in bold font and underlined. 
2.1.4.  Reverse transfection protocol  
The protocol used for HAEC transfection was adapted from the method described by 
Barker and Diamond 
53
.  HAEC were cultured in Clonetics EGM-2 (Lonza, Walkersville, 
MD).   siRNA (Applied Biosystems, Foster City, CA) was added to a well plate.  The 
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well plate was either frozen overnight or held at room temperature for less than two 
hours.  If the plate was frozen, it was thawed and allowed to equilibrate to room 
temperature prior to use.  siPort NeoFX™ (Applied Biosystems, Foster City, CA) diluted 
in Opti-Mem™ (Lonza, Walkersville, MD) was added to the siRNA plate and allowed to 
incubate at room temperature for 10 minutes.  HAEC grown in a cell culture flask were 
then added to the plate at a seeding density of 4.5 x 10
4
 cells per cm
2
.  The siRNA were 
allowed to transfect the cells for 24 hours.  
2.1.5.  Forward transfection protocol  
siRNA (Applied Biosystems, Foster City, CA) was thawed at room temperature and then 
added to siPort NeoFX™ (Applied Biosystems, Foster City, CA) diluted in Opti-Mem™ 
(Lonza, Walkersville, MD).  The mixture was allowed to incubate at room temperature 
for 10 minutes prior to addition to 96 well plates.  The siRNA were allowed to transfect 
the cells for 24 hours. 
2.1.6.  Interferon protocol  
Frozen recombinant human αA-Interferon and β-Interferon (Calbiochem, San Diego, CA) 
were thawed on ice and diluted in Dulbecco’s Phosphate Buffered Saline (Invitrogen, 
Santa Clara, CA) and serially diluted prior to addition to a 96 well plate.  Virus addition 
followed within 20 minutes of addition of interferon to the well plate. 
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2.1.7.  Luciferase transduction protocol  
Adeno-associated virus, type 2, containing a CMV promoter and firefly luciferase 
sequence (AAV2-Luc) was added to the well plate.  The virus was then allowed to 
transduce the cells for 24 hours.  On the third day, cells were assayed for gene expression 
using the Bright-Glo assay kit (Promega, Madison, WI) following the vendor’s protocol.   
A scrambled siRNA sequence was used as a negative control (Silencer Negative Control 
1; Applied Biosystems, Foster City, CA). 
2.1.8.  Fluorescence transduction protocol  
After 24 hours of exposure to siRNA, adeno-associated virus, type 2, containing a CMV 
promoter and enhanced green fluorescent protein sequence (AAV2-EGFP) was added to 
the plate.  The virus was then allowed to transduce the cells for a minimum of 48 hours 
prior to imaging and flow cytometry analysis. 
2.1.9. Flow Cytometry  
An Accuri C6 Flow Cytometer (Accuri Cytometers, Ann Arbor, MI) was used for 
quantitative analysis of individual cell fluorescence.  Cells were harvested into 
Dulbecco’s Phosphate Buffered Saline (Invitrogen, Santa Clara, CA) and then held on ice 
until measurement.  20,000 counts per sample were recorded. 
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2.1.10. Cell viability assay  
Cells were assayed for viability using the Cell Titer Glo assay kit (Promega, Madison, 
WI) following the vendor’s protocol. 
2.1.11. Quantitative real-time PCR   
Cells were treated with siRNA and were then harvested a day later for total RNA content 
using the Absolutely RNA microprep kit (Stratagene, La Jolla, CA).  Superscript III 
reverse trasnscriptase and oligo(dT) (Invitrogen, Carlsbad, CA) was used to reverse 
transcribe the RNA.  The resulting cDNA was then purified using the Qiagen PCR 
purification kit (Qiagen, Valencia, CA).  The CLIC2 forward primer used was 
CACTACAAGCTAGACGGT and the reverse primer used was 
CCAGGAACGGAGGATT.  The MX1 forward and reverse primers, respectively, were 
CGCAGGGACCGCCTTGGACC and GGGTGGGATGCAGCAGCTGGA.  The IFI44L 
forward primer and reverse primers used were, respectively,  
GGTGGGTCCAGTTGGGTCTGGA and GCACAGTCCTGCTCCTTCTGCC.  The 
IFIT5 forward and reverse primers used were, respectively, 
AGGCTGTTACCCTGAACCCAGAT and GGTCTGTTGTGTGTGGCCTTCT.  The 
GAPDH transcript was used to normalize between samples.  The GAPDH forward 
primer and reverse primers were, respectively, TGCACCACCAACTGCTTAGC and the 
GGCATGGACTGTGGTCATGAG.  A Roche LightCycler (Indianapolis, IN) was used 
to generate a standard curve and optimize PCR conditions for each primer.  The 
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LightCycler FastStart DNA MasterPLUS SYBR Green I kit (Roche, Indianapolis, IN) 
and Light Cycler melting curve analysis was used to perform quantitative real-time PCR. 
2.1.12. Transcription Profiling  
Cells were grown in 24 well plates at a seeding density of 45,000 cells/cm
2
.  Cells were 
harvested using 0.05% Trypsin-EDTA (Invitrogen, Carlsbad, CA) 24 hours after siRNA 
transfection.  Total RNA was purified from cell lysate using the Absolutely RNA kit 
(Agilent, Santa Clara, CA).  For each sample, 0.2-0.3 ug of purified RNA was amplified, 
fragmented, and then hybridized to the Human Gene 1.0ST microarray (Affymetrix, 
Santa Clara, CA)according to the Affymetrix GeneChip Expression Analysis Technical 
Manual protocol. Following hybridization, washing, and staining, the microarray was 
imaged using a confocal scanner with fluorescence excitation at 570 nm.  Two sequential 
scans were conducted and a mean fluorescence signal was calculated.  The resulting 
signals were analyzed using the Affymetrix Microarray Suite 5.0 and default values 
provided by Affymetrix.  Fold change, p-value, and Significance Analysis of 
Microarray
54
 (SAM) q-value were calculated.  Transcripts whose SAM q-value were  less 
than 25 and having a fold-change difference greater than 1.25 (indicating up-regulation) 
or less than -1.25 (indicating down-regulation) were identified. 
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2.1.13. Identification of hexamer seed region in 3’ untranslated 
region   
The UTRdb
55, 56
 contains the untranslated sequences of eukaryotic mRNAs.  The 3’ 
untranslated regions of each of the top 50 genes identified as a possible hit in siRNA 
primary screening as well as the 3’ untranslated regions of genes identified in 
transcription profiling were searched for the presence of the hexamer seed region 5’-
GAAACA-3’. 
2.2.  Results  
2.2.1. Primary and secondary screening  
An siRNA library targeting 5,520 gene sequences was screened as pools (3 siRNA 
pooled per targeted gene) to examine the effect of each targeted gene on AAV2 
transduction of cultured human aortic endothelial cells (HAEC).  Three siRNAs at a 
concentration of 10 nM per targeted gene were pooled (30 nM total) and reverse 
transfected into human aortic endothelial cells (HAEC) in three replicate wells.  At 1 day 
post-siRNA delivery, the HAEC were transduced with AAV2 coding for the firefly 
luciferase gene (AAV2-Luc) at 8.60 x 10
6
 genome copies per well and the luciferase was 
then assayed 24 hr post-transduction (Figure 2.1a).  The Robust Z-factor 
53, 57
 provides a 
metric of the median absolute deviation by which an individual knockdown condition 
(averaged over 3 replicates) differs from the population median (median luminescence 
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signal of 3.9 x 10
3
 RLU).   A total of 50 hits (~1 % hit rate) were scored as those siRNA 
pools with Robust Z-factor > 4.75, corresponding to replicate wells having >8.4-fold 
enhancement of luciferase expression.   
The top 50 hits from the pooled primary screening were confirmed in a secondary screen 
by testing individually each of the three siRNAs (not shown).  In this confirmation test, 
each individual siRNA was added such that the siRNA concentration prior to virus 
addition was 30 nM (See Appendix Table A1 for siRNA sequences).  A total of 10 
targeted genes were confirmed that had at least one siRNA sequence providing 
significant improvement in transduction efficiency (Figure 2.1b).  Three of the top ten 
gene hits (SLC13A4, SLC5A2, SLC5A3) came from solute carrier families, with 
sequence B against SLC5A2 resulting in greater than 6-fold enhancement of luciferase 
transgene expression.  Sequence C against CLIC2 resulted in greater than 4-fold 
enhancement of transgene expression.   
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Figure 2.1.  Primary and secondary screening for siRNA enhancers of AAV 
transduction.  (a) Robust Z-factor for 5,520 siRNA pools (average of three replicates) 
examined in primary screen for enhancement of AAV transduction as detected by 
enhancement of the luciferase transgene.  A cut-off of Robust Z-factor > 4.75 defined 50 
hits (red).  Data from untreated wells (average of eight replicates) is shown on the right.  
Z-factor = 0 (median) and Z = 3.0 are marked as a reference.  (b) A total of 10 of the top 
50 pooled screening hits were confirmed as enhancers of AAV transduction when each 
siRNA (sequences A, B, C) of each pool was tested individually.  At least one of the 
three sequences tested in each pool resulted in a significant enhancement of luciferase 
expression.    
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Cell viability following knockdown with SLC5A2 sequence B and CLIC2 sequence C 
was unchanged (Figure 2.2), indicating that enhancements in transgene expression were 
not likely due to toxicity of a particular siRNA sequence.  
 
 
Figure 2.2.  Viability of HAEC following siRNA knockdown with indicated 
sequences.  HAEC were reverse transfected with indicated siRNA sequences and were 
assayed for viability 24 hours later. 
2.2.2. Off-target effect of siRNA sequences against CLIC2 
Since only sequence C against CLIC2 enhanced transgene expression, we used qRT-PCR 
to verify the extent of CLIC2 mRNA knockdown.  As shown in Figure 2.3, the amount 
of CLIC2 mRNA knockdown was similar for each sequence at siRNA concentrations of 
30 nM or 100 nM.  We conclude that the mechanisms by which sequence C caused a 
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substantial, dose-dependent increase in AAV2 transduction was not due to the reduction 
in CLIC2 mRNA.   
 
Figure 2.3.   Demonstration of off-target mechanism of action of CLIC2 siRNA. (a) 
qRT-PCR measurement of CLIC2 mRNA knockdown in HAEC at 24 hr following 
transfection with 3 different siRNA sequences at concentrations of 30 nM and 100 nM, 
normalized against GAPDH mRNA signal.  (b) Luciferase luminescence relative to 
scrambled siRNA negative control for CLIC2 siRNA sequences A, B, and C used at four 
concentrations of 10, 30, 50, and 100 nM.  AAV transgene expression was uncorrelated 
with CLIC2 mRNA knockdown. 
2.2.3. Seed region off-target effects 
Analysis of the top siRNA sequence hits from single siRNA confirmation screening 
revealed that 3 of the top 5 shared an identical nucleotide sequence at positions 2-7 of the 
antisense strand and that a fourth siRNA shared positions 2-6 with those sequences 
(Table 2.1).  To investigate if the observed off-target effect stemmed from this 
U2GUUUC7 seed region of the antisense strand, three siRNAs consisting of the CLIC2 
sequence C containing point mutations were examined (Table 2.1).  These siRNAs were 
then transfected into HAEC at a range of concentrations from 10 to 100 nM and AAV2-
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Luc was added 24 hr later (Figure 2.4).  Where the point mutation was introduced into 
position 1or position 14 of the sequence, increases in transduction were comparable to the 
original CLIC2 sequence C.  However, when the U4A point mutation was introduced into 
the middle of the hexamer seed region, the siRNA sequence performance was similar to 
the negative control and did not display the increases in transduction efficiency observed 
with the other sequences.   Comparison of knockdowns with the CLIC2 sequence C and 
the mutated CLIC2 sequence C in which the nucleotide at position four (U4A) indicates a 
microRNA-like mechanism for the off-target siRNA mediated enhancement of luciferase 
expression. 
 
Figure 2.4.    Hexamer region of CLIC(C) antisense strand mediates enhanced 
AAV2 transgene expression. Effect of CLIC2 siRNA sequence C and CLIC2(C) siRNA 
mutants on AAV2 transduction of HAEC, normalized to scrambled siRNA negative 
control.    
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2.2.4. Identification of hexamer seed region in 3’ untranslated 
region  
The 3’ untranslated region of genes identified in primary screening were searched for 
complementarity to the hexamer seed region 5’-UGUUUC-3’ (the sequence 5’-
GAAACA-3’ was searched for in the 3’ untranslated region).  The results are presented 
in Appendix Table A1.  No trends were found with regards to the presence or absence of 
this sequence within the 3’ untranslated region. 
2.2.5. Transcription profiling following siRNA transfection 
implicate interferon pathways 
Additional off-target effects of siRNA can arise through global phenotypic changes in the 
mRNA profile due to the siRNA.  Differences in the mRNA expression profile between 
CLIC2(C) and CLIC2(C)-U4A mutant sequences due to off-target effects specific to the 
hexamer seed region were tested by mRNA profiling.  In comparing the HAEC response 
to CLIC2 sequence C versus U4A mutant siRNA sequence (no AAV2 added), a total of 
28 transcripts were enhanced, while 40 transcripts were decreased (Appendix Table A2)   
Several transcripts related to the interferon pathway were downregulated:  interferon-
induced protein 44-like (IFI44L), interferon-inducible myoxovirus resistance1 (MX1), 
and interferon-induced protein with tetratricopeptide repeats (IFIT5).  The IFI44L and 
MX1 transcripts were specifically among the top 5 transcripts identified, and the top 2 for 
which a known function or pathway could be assigned.  Transfection with CLIC2 
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sequence C siRNA resulted in a reduction of IFI44L, MX1, and IFIT5 mRNAs relative to 
transfection with CLIC2-U4A mutant siRNA as confirmed by qRT-PCR (Figure 2.5). 
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Figure 2.5.  HAEC were transfected with CLIC2 sequence C and qRT-PCR was 
used to quantify relative levels of IFI44L, MX1, and IFIT5 mRNA. Results indicate 
that each of the three mRNAs was knocked down in the presence of CLIC2 sequence C, 
but not in the presence of the mutated siRNA sequence. 
 
To further investigate the interferon pathway which is a known modulator of viral 
processes 
58-60
, several knockdowns were conducted.  IFI44L, MX1, and IFIT5 
knockdowns when tested individually did not result in an enhancement of AAV2-Luc 
transduction (not shown), indicating that CLIC2 sequence C siRNA creates a complex 
phenotype that results in enhanced transgene expression.  In an additional test of 
interferon pathway processes, two unique siRNA sequences targeting the interferon 
(alpha, beta, and omega) receptor 2 (IFNAR2) led to an increase in virus transduction 
(Figure 2.6a).  In contrast, the addition of recombinant alpha interferon and beta 
interferon directly into the cell culture at the time of transduction led to a decrease in 
transgene expression (Figure 2.6b) with no change in cell viability (not shown). 
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Figure 2.6.  Effect of Type 1 interferons.  (a) The addition of alpha interferon or beta 
interferon leads to a dose-dependent decrease in AAV2 transduction. (b) Knockdown of 
interferon (alpha, beta, omega) receptor 2 using two different siRNA sequences leads to 
an increase in viral transduction. 
a 
b 
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2.2.6. Human Airway Culture  
We evaluated if the enhancing effect of CLIC sequence C siRNA was cell-specific by 
testing enhancement of AAV2 transduction of a human bronchial epithelium.  In order to 
test the effectiveness of these siRNA sequences in a primary cell line, both the SLC5A2 
sequence B and CLIC2 sequence C were evaluated in human bronchial epithelium using 
adeno-associated virus type 2 coding for enhanced green fluorescent protein (EGFP), 
followed by evaluation using fluorescence microscopy and flow cytometry.  At the 
highest siRNA concentration tested, an increase in fluorescence of 27% was observed for 
SLC5A2 sequence B and an increase in fluorescence of 61% was observed for CLIC2 
sequence C (Figure 2.7).  Although the siRNA sequences were identified using HAEC 
cells, the results were not specific to the endothelium and may be useful for gene therapy 
applications in respiratory diseases such as cystic fibrosis.  These results also confirm that 
the enhancing effects were not unique for the firefly luciferase reporter gene product 
since SLC5A2 sequence B and CLIC2 sequence C siRNAs increased in fluorescence 
from EGFP as measured using flow cytometry and were consistent with the luciferase 
enhancements. 
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Figure 2.7.   siRNA mediated enhancement of AAV2 transduction of human 
epithelial cells. Fluorescence microscopy images and flow cytometry data for human 
bronchial epithelium culture treated with (a) scrambled siRNA negative control, (b) 
SLC5A2 sequence B and (c) CLIC2 siRNA sequence C and then transduced with AAV2 
containing EGFP. 
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2.2.7. Combination effects   
Two experiments were carried out in which the effect of pair-wise combinations of 
siRNAs was examined.  The total siRNA concentration used was constant at 50 nM.  In 
the first of these experiments, pair-wise combinations of the top single siRNA sequence 
for each of the top ten genes were examined (Figure 2.8a).  In the second, pair-wise 
combinations of the three siRNA sequences for the top three genes (CLIC2, GPR124, and 
SLC5A2) were examined (Figure 2.8b).  As expected, SLC5A2 sequence B and CLIC2 
sequence C both provided high results both alone and in combination with other 
sequences.  GPR124 sequence B also provided a strong signal.  In each of the two 
experiments, the highest signal came from a mixture of two siRNA sequences.   For 
example, GPR124 sequence A provided 2-fold improvement when used on its own, and 
CLIC2 sequence C provided 4.3-fold improvement on its own, but the combination gave 
5.6-fold improvement.  The pairwise tests generally resulted in additive enhancement but 
not synergistic enhancements. 
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Figure 2.8.  Pairwise interactions among confirmed siRNA hits.  Heat map of 
pairwise interactions between siRNA sequences (total siRNA concentration/well = 50 
nM) for the top 10 confirmed hits (a) or the 3 different sequences against the top 3 hits 
(b). 
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2.2.8. Co-administration of siRNA with AAV 
In order to examine the use of siRNA in combination with adeno-associated viral gene 
delivery, two experiments were performed in which the siRNA was co-administered with 
the viral vector.  In the first, the virus was pre-mixed with the siPort/siRNA mixture and 
then cells were added within thirty minutes (Figure 2.9a).  In the second, the virus was 
added immediately following the addition of cells to the siPort/siRNA mixture (Figure 
2.9b).  The main difference between these two experiments was the exposure of virus to a 
higher concentration of siPort/siRNA for a short period of time in the pre-mixed 
experiment.  The experiments showed similar results to each other, and additionally 
followed the same general trend of results observed for the standard transduction protocol 
in which 24 hours elapsed between addition of siRNA and addition of virus.  For the 
SLC5A2 sequence B and CLIC2 sequence C sequences, increases in viral transduction in 
the range of 50 to 150% were observed for the 50 nM condition.    
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Figure 2.9.  Coadministration of adeno-associated virus serotype 2 and short 
interfering RNA (siRNA) to human aortic endothelial cells enhances transgene 
expression. (a) Virus was premixed with siRNA lipoplexes and then added to cells. (b) 
Cells were reverse transfected and virus was immediately added after adding cells to 
siRNA formulation.  
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2.2.9. Common screening hits between Adenovirus and AAV2 
Three primary screening hits were common to both an adenovirus screen and the AAV2 
screen.  These three hits were subject to a follow-up experiment.  The top two out of 
these, ARF GTPase-acting protein (GIT2) and Olfactory Receptor 51E1 (OR51E1), were 
each screened using three novel siRNA sequences not present in the original screen.  A 
third, phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide 
synthetase, phosphoribosylaminoimidazole synthetase (GART), had previously been in 
confirmatory studies using the original siRNA sequences from primary screening.  This 
third enhancer was retested using those original siRNA sequences.  As demonstrated in 
Figure 2.11, siRNA enhancement from these three genes was minimal.   
 
Figure 2.10.    siRNA primary screening hits common to adenovirus and adeno-
associated virus screens. Effect of GART, GIT, OR51E1 on AAV2 transduction of 
HAEC, normalized to scrambled siRNA negative control.    
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2.2.10. Serotype-Independence of Enhancement 
In order to better understand the mechanism for enhancement of the top siRNA screening 
hits, HAEC transfected with SLC5A2 sequence B or CLIC2 sequence C were then 
transduced with either AAV2 or pseudotyped AAV2/1, which contains the AAV2 
genome packaged into an AAV type 1 capsid.  As demonstrated in Figure 2.11, the 
siRNA enhancement was independent of the capsid selected. 
 
 
Figure 2.11. Pseudotyped AAV2/1 vector shows similar transduction trends to 
AAV2 vector.  Cells treated with 50 nM siRNA were transduced with either AAV2 or 
AAV2/1 at a multiplicity of infection of 10,000, followed by Bright-Glo Assay. 
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2.3. Discussion 
The use of siRNA high throughput screening targeting 5,520 genes allowed the 
identification of enhancers of adeno-associated viral gene delivery.    By screening pools 
of 3 siRNAs per targeted gene in triplicate, a stringent Robust Z-score > 4.75 provided 
for a ~ 1 % hit rate.  When individual siRNA sequences were retested, only 10 of the 50 
targeted genes (20 % confirmation rate) resulted in AAV-Luc enhancements when the 
siRNA sequences were tested individually (Figure 2.1).  One of the strongest inducers 
was the CLIC(C) sequence which had a beneficial action on transduction that was not 
correlated to CLIC mRNA knockdown (Figure 2.3), indicating an off-target effect.  
Inspection of a number of the confirmed siRNA sequences that enhanced transgene 
expression led to the identification of a common hexamer seed region [5’-U2GUUUC7-
3’] (Table 1).  The U4A mutation in this hexamer seed region of the antisense strand 
destroyed the enhancing activity of the CLIC(C) siRNA (Figure 2.4), indicating an 
important role for off-target microRNA-like silencing as a mechanism enhancing AAV2 
transduction. At present, no off-target silenced mRNAs have been identified that result in 
the enhanced transduction.  The off-target effects of siRNAs were beneficial to AAV2 
transduction of both human endothelium and human bronchial epithelium (Figure 2.7).   
Interestingly, siRNA sequences when used together provided additive benefits to AAV2 
transduction (Figure 2.8) and never resulted in cross-antagonism (< 1-fold enhancement).   
 Several of the top mRNA levels that are down-regulated specifically by the CLIC(C) 
siRNA sequence but not the CLIC(C)-U4A mutant siRNA were interferon-inducible 
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genes (IFI44L, MX1, and IFIT5).  Due to this result, the interferon pathway was further 
explored and knockdown of the interferon (alpha, beta, omega) receptor 2 was shown to 
improve transduction (Figure 2.6a).  This receptor is activated by type I interferons.  The 
type I interferons serve as an early warning system in anti-viral defense.  In response to a 
stimulus from a pathogen, type I interferons are synthesized and secreted 
60
.  The type I 
interferons then bind to receptors IFNAR1 or IFNAR2, and the janus kinase (JAK), 
tyrosine kinases (Tyk2), and signal transducers and activators of transcription (STAT1 
and STAT2) comprise the downstream pathways leading to production of interferon-
induced proteins 
58, 59, 61, 62
.  Many proteins are induced by the interferons, although a 
main pathway consists of the expression of protein kinase R (PKR).  PKR then inhibits 
protein synthesis by inducing RNAse L to destroy RNA and by activating eukaryotic 
initiation factor 2 (eIF2) to lessen protein translation 
63, 64
. Other mechanisms additionally 
recruit the adaptive immune response 
58
.  Notably, a current literature search shows 
several studies in which AAV has been used to deliver interferon-β for cancer gene 
therapy 
65-67
.  These studies show promising results; however the results presented in this 
paper suggest that caution should be used when combining the AAV vector with 
interferon, due to the potential that the interferon could inhibit future re-administration of 
the vector. 
With respect to therapeutic strategies to enhance transduction, we report that co-
administration of siRNA lipoplexes with AAV2 results in enhanced transgene expression 
(Figure 2.9), suggesting that the enhancement is due to siRNA-modulated pathways 
distal of changes in receptor engagement, endocytosis, or endosome escape.   We 
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conclude that siRNA sequences containing the hexamer seed region [5’-U2GUUUC7-3’] 
result in a complex alteration of phenotype involving both translational silencing and 
multiple off-target mRNA knockdowns that together modulate the interferon pathway 
response to viral infection.  However in regard to gene therapy, this alteration of 
phenotype can lead to enhancements in AAV transgene expression in human endothelium 
and epithelial cells. 
Although the GART, GIT, and OR51E1 genes appeared promising based on their 
common appearance in hits from adenovirus and AAV2 screens, further study showed 
limited enhancement from these genes (Figure 2.10). 
Enhancement of the pseudotyped vector AAV2/1 by the top screening hits SLC5A2 
sequence B and CLIC2 sequence C was comparable to enhancement by the AAV2 vector 
(Figure 2.11).  The only difference between these two vectors is the capsid and its 
associated cellular receptors.  The primary receptor for AAV2 is heparan sulfate 
proteoglycan, whereas the main receptor for AAV2/1 is sialic acid.  This suggests that the 
enhancement activity of these sequences is unrelated to virus/cell surface receptor 
interaction. 
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Chapter 3 
3. Chemical Compound Screen 
3.1. Abstract 
A total of 2,320 molecules from two different chemical compound libraries were 
screened for their ability to enhance adeno associated virus type 2 transduction of 
cultured human endothelium.  Of these compounds, 20 provided two-fold or greater 
enhancement at a concentration of 10 µM in primary screening. 
3.2. Introduction 
The interaction of adeno-associated virus with a cell consists of a pathway which 
includes surface receptor binding, endocytosis, endosomal escape, accumulation in the 
perinuclear space, transport into the nucleus, capsids uncoating, the synthesis of the 
second strand of DNA, transcription of the viral DNA to RNA, transport of the RNA out 
of the nucleus, and translation of the RNA.  In chapter 2, we discussed a high throughput 
screen for the identification of siRNA enhancers of this process.  In this chapter, we 
adopted a high throughput screening approach to identify chemical compounds which 
enhance the AAV2 transduction process.  We then explore mechanistic details of selected 
compounds. 
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Cells were treated with compounds from the Sigma Library of Pharmacologically Active 
Compounds (LOPAC) and National Institute of Neurological Disorders and Stroke 
(NINDS) followed by addition of adeno-associated virus type 2 in order to identify 
compounds which may enhance viral transduction.  A total of 2,230 compounds were 
screened. 
20 compounds were identified as primary screening hits which enhanced viral 
transduction greater than two-fold in primary screening.   These hits included several 
families of compounds.  Of those compound families, antioxidants, nucleoside analogs, 
cell cycle arrestors, and alkylating agents were examined in more detail.  Additionally, 
metal chelation as a mechanism was investigated based on one of the top primary 
screening hits. 
3.3. Materials and Methods 
3.3.1. Cell culture  
Human Aortic Endothelial Cells (HAEC; Lonza, Walkersville, MD) were cultured in 
supplemented Clonetics EGM-2 (Lonza, Walkersville, MD) at 37ºC and 5% CO2.  Prior 
to screening, cells were rinsed with Dulbecco’s phosphate-buffered saline and incubated 
with 0.05% Trypsin-EDTA (Invitrogen, Santa Clara, CA), then seeded onto 384 well flat 
bottom plates at a concentration of 860 cells per well in 15 ul of media (BD Bioscience, 
Franklin Lakes, NJ).     
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3.3.2. Compound libraries  
The LOPAC (Sigma-Aldrich, Milwaukee, WI) and NINDS (Microsource Discovery 
Systems, Gaylord, CT) libraries were used for screening.  LOPAC contains 1,280 
chemicals at a concentration of 10 mM of compound suspended in 100% DMSO.  The 
NINDS library contains 1,040 chemicals at a concentration of 10 mM of compound 
suspended in 100% DMSO. 
A pin tool was used to transfer 0.1 microliters from the plates into a dilution plate 
containing 25 ul of media, resulting in a final concentration of 40 µM of compound in 
media.  From these dilution plates, 5 ul of diluted compound was added to the cells in 15 
ul of media, resulting in 20 ul of cells containing a concentration of 10 µM of compound.  
The final DMSO concentration per well after compound was mixed with cells was 0.1%.  
The cells were incubated in the presence of chemical compounds for 24 hours prior to the 
addition of virus. 
For further confirmation of screening results, chemicals were individually purchased 
from Sigma (Milwaukee, WI) and dissolved in phosphate buffered saline if soluble in 
aqueous solvents.  Compounds that were not soluble in aqueous solvents were dissolved 
in DMSO and subsequently added to cells in media such that the final DMSO 
concentration was 1%.  A list of specific compounds and catalog numbers investigated is 
provided in the Appendix. 
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3.3.3. Luciferase transduction protocol  
Adeno-associated virus, type 2, containing a CMV promoter and firefly luciferase 
sequence was added to the well plate at a multiplicity of infection of 10,000 viral genome 
copies per cell.  The virus was then allowed to transduce the cells for 24 hours.  On the 
fourth day following initial cell seeding, cells were assayed for gene expression using the 
Bright-Glo assay kit (Promega, Madison, WI) following the vendor’s protocol.  
3.3.4. Fluorescence transduction protocol  
After 24 hours of exposure to chemicals, adeno-associated virus, type 2, containing a 
CMV promoter and enhanced green fluorescent protein sequence was added to the plate. 
The virus was allowed to transduce the cells for 24 hours and then the media containing 
virus and chemicals was replaced with fresh media.  Microscopy images and flow 
cytometry took place 24 hours after the media was replaced. 
3.3.5. Flow Cytometry  
An Accuri C6 Flow Cytometer (Accuri Cytometers, Ann Arbor, MI) was used for 
quantitative analysis of individual cell fluorescence.  Cells were harvested into 
Dulbecco’s Phosphate Buffered Saline (Invitrogen, Santa Clara, CA) and then held on ice 
until measurement.  20,000 counts per sample were recorded. 
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3.3.6. Cell viability assay  
Cells were assayed for viability using the Cell Titer Glo assay kit (Promega, Madison, 
WI) following the vendor’s protocol. 
3.3.7. Total Protein Quantification 
The total amount of protein present in the sample was measured by BCA assay.  Cells 
were released from the well plate using 0.25% Trypsin followed by the addition of media.  
They were then centrifuged to create a pellet which was washed with saline followed by 
the addition of  lysis buffer containing 100 mM potassium phosphate, pH 7.8 and 2% 
Triton-X 100.  Cells were incubated in lysis buffer for 40 minutes prior to BCA assay.  
The assay was conducted according to manufacturer’s instructions using the Pierce BCA 
Assay Kit (Thermo Scientific, Rockford, IL). 
3.3.8. DNA Purification 
Cells treated with compound followed by AAV2-EGFP were then harvested two days 
later for total DNA content using the DNeasy Blood & Tissue Kit kit (Qiagen, Valencia, 
CA). 
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3.3.9. cDNA Synthesis 
Cells treated with compound followed by AAV2-EGFP were then harvested two days 
later for total RNA content using the Absolutely RNA microprep kit (Stratagene, La 
Jolla, CA).  Superscript III reverse trasnscriptase and oligo(dT) (Invitrogen, Carlsbad, 
CA) were used to reverse transcribe the RNA, resulting in cDNA. 
3.3.10. Quantitative Real Time PCR 
Purified DNA and synthesized cDNA were then amplified using the Roche LightCycler 
(Roche, Indianapolis, IN).  LightCycler FastStart DNA MasterPLUS SYBR Green I kit 
(Roche, Indianapolis, IN) and Light Cycler melting curve analysis was used to perform 
quantitative real-time PCR.  The EGFP DNA was measured using forward primer 
CGACAACCACTACCTGAGCA and the reverse primer 
GAACTCCAGCAGGACCATGT.  GAPDH DNA or cDNA was used to normalize 
between samples according to the sample type used.  The GAPDH forward primer and 
reverse primers were, respectively, TGCACCACCAACTGCTTAGC and the 
GGCATGGACTGTGGTCATGAG.  
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3.4. Results 
3.4.1.  Primary screening 
2,320 compounds from the two screening libraries were examined for the effect of each 
chemical compound on AAV2 transduction of cultured human aortic endothelial cells.  
Cells were transferred into 384 well culture plates, and one day later chemicals dissolved 
in DMSO were transferred into each well such that the final concentration of DMSO in 
each well was 0.1%.  On the next day, the HAEC were transduced with AAV2 coding for 
the firefly luciferase gene (AAV2-Luc) at 8.60 x 10
6
 genome copies per well and the 
luciferase was then assayed 24 hours post-transduction (Figure 3.1a).  These compounds 
are listed in Appendix 1.  The Robust Z-factor 
53, 57
 provides a metric of the median 
absolute deviation by which an individual chemical (averaged over 2 replicates) differs 
from the population median.   Figure 3.1b below shows representative data for a single 
plate as well as the Z-score plot of the two replicates.  Compounds with Z-score greater 
than 3 for both replicates are included in the box at the top right of the figure. 
Compounds with Z-score less than -3 were not found. 
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Figure 3.1.    Chemical compound primary screening results.  a: Results for a 
representative 384 well plate.  Hits of three standard deviations above the mean for the 
plate are circled in red.  b: Overall primary screening results.   
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The top hits from primary screening were further examined through the individual 
addition of these compounds to cells in 96 well plates.  The most promising compounds 
from that work, as well as related compounds, were examined in more detail, including 
dose-response testing and viability testing. 
From the primary screening results, it appeared that several families of related 
compounds emerged as hits.  Ellagic acid, caffeic acid phenethyl ester, 7,4-
dihydroxyflavone, daidzein, resveratrol, and 7,2-dihydroxyflavone are all antioxidant 
compounds.
68
  Tyrphostin AG 698, Tyrphostin AG 490, and Tyrphostin AG 537 are all 
EGFR protein tyrosine kinase inhibitors.  4,5-dianiliophthalamide is additionally a 
protein tyrosine kinase inhibitor.  Cell cycle arrestors were also examined due to the cell 
cycle regulatory effects of daidzein and 1,10-phenanthroline.  5-bromo-2-deoxyuridine, 
vidarabine, and 3-azido-3-deoxythymidine are all nucleoside analogs.  Carboplatin and 
melphalan are both alkylating agents.  As previous reports had investigated EGFR protein 
tyrosine kinase inhibitors in detail,
69, 70
 we chose to focus on antioxidants, nucleoside 
analogs, and alkylating agents.  Additionally, as the metal chelator 1,10-phenanthroline 
provided a very strong signal in primary screening, we also included metal chelators in 
our investigation. 
3.4.2. Mechanistic Studies 
In order to probe the mechanism for several of the top hits, cells were treated with 10 µM  
of compound and transduced with AAV-EGFP 24 hours later.  After 48 hours, cells were 
examined by fluorescence microscopy, flow cytometry, PCR for quantification of EGFP 
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DNA, qRT-PCR for quantification of EGFP RNA, and BCA assay for quantification of 
total cellular protein.  Results are given in Table 3.1 below. 
 Normalized 
Virus DNA 
(EGFP) 
Normalized 
Virus RNA 
(EGFP) 
Normalized 
Average 
Fluorescence 
Normalized 
Total 
Protein 
1% DMSO* 1.0 1.0 1.0 1.0 
Ellagic acid* 1.0 61.1 33.4 2.0 
Tyrphostin 698* 0.2 0.5 2.0 1.0 
Melphalan* 0.6 2.7 2.6 1.7 
Vidarabine 0.7 2.8 1.4 0.6 
5-bromo-2'-
deoxyuridine 
0.8 5.1 2.3 0.8 
1,10-phenanthroline 1.9 4.6 2.3 0.9 
Carboplatin 1.0 1.7 1.2 0.7 
MOI 0 (no virus) 0.0 0.0 0.1 1.0 
MOI 1,000 0.1 0.2 0.2 1.0 
MOI 10,000 1.0 1.0 1.0 1.0 
MOI 100,000 10.0 2.0 1.5 0.8 
 
Table 3.1.  Normalized viral DNA, viral RNA, average fluorescence per cell, and total 
protein per well for selected compounds.  For RNA and DNA measurements, the ratio of 
EGFP signal to GAPDH signal is calculated for each sample, and then that ratio is 
normalized to control.  Conditions with an asterisk (*) contained 1% DMSO in the well 
and were normalized to the DMSO control.  All other conditions are normalized to the 
MOI 10,000 sample. 
3.4.3. Tyrosine kinase inhibitors 
Three of the compounds found (Tyrpohstin AG 490, Tyrphostin AG 537, and Tyrphostin 
AG 698) are epidermal growth factor receptor (EGFR) protein tyrosine kinase inhibitors.  
EGFR is a cell surface receptor which when activated by ligand homodimerizes, forming 
a kinase on the internal surface of the cell membrane.  It autophosphorylates and serves 
as a kinase for several other pathways.
71
  Consistent with these results, previous work by 
Zhong and colleagues has shown that the addition of the EGFR protein tyrosine kinase 
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inhibitor Tyrphostin 23 increased AAV2 transduction.  They found two specific 
mechanisms by which EGFR inhibition enhanced transduction; through decreased 
ubiquination of AAV2 capsids and through decreased FK506-binding protein inhibition 
of AAV2 second-strand DNA synthesis.
70
   The existence of many EGFR protein tyrosine 
kinase inhibitors on the list of primary screening hits supports the finding that EGFR 
inhibition enhances transduction, and as shown in Table 3.1, reporter gene expression is 
increased when Tyrphostin 698 was exposed to cells.  However, because previous reports 
investigated the effect of EGFR protein tyrosine kinase inhibitors in great detail, the 
current work did not study these compounds in depth. 
3.4.4. Antioxidants 
Several antioxidant compounds were identified in primary screening, including ellagic 
acid, caffeic acid phenethyl ester, 7,4-dihydroxyflavone, and 7,2-dihydroxyflavone.  
Ellagic acid was of particular interest as it was the strongest hit in primary screening and 
it continued to perform well in follow-up studies (Figure 3.2 and Figure 3.3).  In order 
to follow-up on the success of ellagic acid as an enhancer, other compounds with similar 
functionality were examined.  Caffeic acid, an antioxidant which demonstrated some 
enhancement during primary screening, showed poor performance in a dose-response 
curve (Figure 3.4a).  Ascorbic acid (vitamin C) was added to growth media, but no 
enhancement of viral transduction was observed (Figure 3.5).  N-acetyl cysteine was also 
added with no enhancement of viral transduction (Figure 3.6).  Other anti-oxidants 
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including beta-carotene and bilirubin were also examined, but poor solubility in DMSO 
or aqueous solution prevented their experimental use (data not shown).  
Although ellagic acid is primarily considered as an antioxidant compound, it also serves 
as a tyrosine protein kinase inhibitor, can induce cell cycle arrest, and has intercalating 
properties.
72-75
  Due to the inability of other antioxidant compounds to facilitate adeno-
associated virus transduction, it appears that the enhancement effect of ellagic acid is 
likely due to other effects. 
3.4.4.1. Ellagic Acid 
Ellagic acid was the top hit in primary screening and continued to perform well in dose-
response studies (Figure 3.2a).  Ellagic acid showed an impressive level of enhancement 
in high throughput screening, and it continued to show dose-dependent enhancement 
during follow-up studies.  However, ellagic acid also demonstrated limitations, primarily 
in solubility and toxicity.  Dissolution of ellagic acid at concentrations up to 10 mM in 
either DMSO or aqueous solution was extremely challenging, and most studies were 
performed by dissolving ellagic acid directly in media and replacing the growth media in 
the well with filtered growth media containing ellagic acid at the required concentration.  
Differences in enhancement and toxicity between experimental runs may have been due 
to variability caused by the difficulty in dissolving ellagic acid at the required 
concentration. 
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a)  
 
b) 
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c) 
 
Figure 3.2 Ellagic acid luciferase assay and viability results.  a) Ellagic acid was 
dissolved at a concentration of 100 µM in media, serially diluted in media, and added to 
HAEC.  24 hours later, adeno-associated virus was added, followed by luciferase assay 
after another 24 hours.  b) Normalized cell viability following 48 hours of cell exposure 
to ellagic acid dissolved in media.  c) AAV serotype 2, 2/1, and 2/9 were added to HAEC 
following treatment with ellagic acid. 
 
HAEC treated with 10 µM  ellagic acid were additionally subject to transduction with 
AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow 
cytometry, and BCA assay.  As shown in Table 3.1, the amount of viral DNA measured 
in the cell was the same as the 1% DMSO control, whereas viral RNA and fluorescence 
was greatly increased (61 fold change and 33 fold change, respectively).  The total 
protein per well as measured by BCA assay increased two-fold. 
Because the viral RNA and fluorescence levels changed so dramatically, the PCR data 
was examined more closely for insight into mechanism to determine whether this result 
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was a global increase in protein level or restricted to the increase in viral RNA and 
reporter gene signal (Table 3.2).  The increase in GAPDH RNA and the large normalized 
GAPDH RNA/GAPDH DNA value, in combination with the two-fold increase in protein 
quantity by BCA assay, suggests that the results may be related to a global increase in 
overall protein.  A previous report also described an increase in GAPDH mRNA and total 
protein levels as a result of ellagic acid exposure.
75
 
 GAPDH 
DNA 
GAPDH RNA 
(from cDNA) 
GAPDH RNA/ 
GAPDH DNA 
1% DMSO* 1.0 1.0 1.0 
Ellagic acid* 0.8 8.3 9.7 
Tyrphostin 698* 3.3 0.4 0.1 
Melphalan* 0.9 0.01 0.02 
Vidarabine 4.3 0.1 0.03 
5-bromo-2'-
deoxyuridine 
2.2 0.3 0.1 
1,10-phenanthroline 0.7 0.1 0.1 
Carboplatin 1.1 0.8 0.7 
MOI 0 (no virus) 4.3 0.7 0.2 
MOI 1,000 1.9 1.1 0.6 
MOI 10,000 1.0 1.0 1.0 
MOI 100,000 1.3 0.1 0.1 
  
Table 3.2 Normalized values for quantitative real time PCR measurement of GAPDH DNA, 
GAPDH RNA (by measurement of cDNA), and the ratio of RNA/DNA.  Compounds 
indicated with an asterisk have been normalized by the 1% DMSO measurement, 
whereas others were normalized by the MOI 10,000 condition. 
 
Figure 3.3 provides corresponding information for fluorescence microscopy and flow 
cytometry.  As compared with the 1% DMSO control, the cells treated with ellagic acid 
are elongated and much more fluorescent (Figure 3.3a,b).  Flow cytometry showed more 
granularity in ellagic acid treated cells, as indicated by an increased side scatter 
measurement (Figure 3.3c,d).  An overlay of the fluorescence clearly shows that the 
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ellagic acid treated cells have much higher levels of fluorescence following transduction 
with AAV2-EGFP (Figure 3.3e).    
 
 
Figure 3.3.  Fluorescence microscopy images and flow cytometry data for HAEC 
treated with ellagic acid followed by AAV2-EGFP transduction.  a. Image of HAEC 
treated with 1% DMSO followed by AAV2-EGFP.  b. Image of HAEC treated with 
ellagic acid in 1% DMSO followed by AAV2-EGFP.  c. Forward and side scatter results 
for HAEC treated with 1% DMSO followed by AAV2-EGFP from flow cytometry.  d. 
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Forward and side scatter results for HAEC treated with ellagic acid in 1% DMSO 
followed by AAV2-EGFP from flow cytometry.  e. Histogram overlay of fluorescence 
area for HAEC treated with 1% DMSO (black) and ellagic acid in 1% DMSO followed 
by HAEC treated with AAV2-EGFP (red). 
 
3.4.4.2. Caffeic Acid Phenethyl Ester 
Caffeic acid demonstrated a 2.5 fold enhancement in primary screening (Appendix 
Table A4) and was therefore examined more closely for a dose response.  Additionally, 
caffeic acid phenethyl ester is an antioxidant compound, which allowed further probing 
of the potential for antioxidants to serve as a class of enhancing molecules.
76
  Figure 3.4a 
below shows that the compound only moderately benefited viral transduction, while 
Figure 3.4b demonstrates that cell viability was unaffected by the virus. 
a) 
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b) 
 
Figure 3.4.  Caffeic acid phenethyl ester results.  a) Caffeic acid phenethyl ester was 
dissolved at a concentration of 10 mM in DMSO, serially diluted in DMSO, and added to 
HAEC cells in media such that the final DMSO concentration in each well was 1%.  24 
hours later, adeno-associated virus was added, followed by luciferase assay after another 
24 hours.  b) Viability of HAEC following 48 hours of exposure to caffeic acid dissolved 
in DMSO. 
 
3.4.4.3. Ascorbic acid 
In order to further examine antioxidant functions, ascorbic acid (vitamin C) was added to 
cells followed by treatment with virus containing the luciferase reporter gene.  As shown 
in Figure 3.5 below, the addition of ascorbic acid had no effect on viral transduction. 
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Figure 3.5. Ascorbic acid luciferase assay dose response results.  Ascorbic acid was 
dissolved at a concentration of 100 µM in media, serially diluted in media, and added to 
HAEC.  24 hours later, adeno-associated virus was added, followed by luciferase assay 
after another 24 hours. 
 
3.4.4.4. N-acetyl cysteine 
N-acetyl cysteine is another antioxidant compound.
77
  It was additionally tested in order 
to probe possible antioxidant enhancement of AAV2 transduction.  The compound 
appears to have a moderate effect at best, most likely explained by an artifact of the 
experimental procedure (edge effects), as shown in Figure 3.6. 
57 
 
 
Figure 3.6. N-acetyl cysteine luciferase assay dose-response results.  N-acetyl cysteine 
was dissolved at a concentration of 100 µM in media, serially diluted in media, and added 
to HAEC.  24 hours later, adeno-associated virus was added, followed by luciferase assay 
after another 24 hours. 
3.4.5. Metal Chelators 
1,10-phenanthroline is a metal chelator which was one of the top hits identified in the 
primary screen.  1,10-phenanthroline was examined in more detail.  Additionally, 
ethylenediaminetetraacetic acid   (EDTA), a commonly used metal chelator, was 
examined to see if enhancement would be observed in other metal chelators. 
3.4.5.1. 1,10-phenanthroline 
1,10 phenanthroline is a metal chelator which inhibits metalloproteases and additionally 
activates p53 transcriptional activity.
78
  1,10-phenanthroline was the second strongest hit 
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identified in primary screening, with a normalized luminescence value of 6.4 (Appendix 
table A4).  Although this compound was capable of providing significant enhancement, it 
was also demonstrated to be toxic to HAEC at values above 3 uM, which explains the 
sharp drop in reported enhancement at high compound doses (Figure 3.7b).  1,10-
phenanthroline enhanced adeno-associated viral transduction for pseudotyped viruses 
AAV2/1 and AAV2/9, suggesting that the response to compound is independent of cell 
surface receptor binding (Figure 3.7c). 
a) 
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b) 
 
c) 
  
Figure 3.7.  Luciferase assay and viability results for HAEC treated with 1,10-
phenanthroline.  a) 1,10 phenanthroline luciferase assay results.  1,10 phenanthroline 
was dissolved at a concentration of 10 mM in DMSO, serially diluted in DMSO, and 
added to HAEC cells in media such that the final DMSO concentration in each well was 
1%.  24 hours later, adeno-associated virus was added, followed by luciferase assay after 
60 
 
another 24 hours.  b) HAEC viability following 48 hours exposure to 1,10 phenanthroline 
dissolved in DMSO.  c) Luciferase assay results for HAEC exposed to 1,10-
phenanthroline followed by AAV2, AAV2/1, or AAV2/9.  Two 1,10-phenanthroline 
concentrations were measured. 
HAEC treated with 10 µM  1,10-phenanthroline were additionally subject to transduction 
with AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow 
cytometry, and BCA assay.  As shown in Table 3.1, the amount of viral DNA measured 
was two-fold higher than in the control sample.  Viral RNA present was additionally 
increased to 4.6 times greater than control, and the average fluorescence was 2.3 times 
higher than in the control.  The total protein in the well was about the same as the control.  
Figure 3.8 provides corresponding information for fluorescence microscopy and flow 
cytometry.  Cells treated with the 1,10-phenanthroline do not show a large morphological 
change as determined by microscopy or by flow cytometry (Figure 3.8a,b,c,d).  An 
overlay of the fluorescence data shows the overall fluorescence profile shifting to the 
right in addition to the appearance of a small group of very highly fluorescent cells. 
(Figure 3.8e). 
Overall, the data suggest that 1,10-phenanthroline does not affect the virus/receptor 
interaction due to the non-serotype specificity, however DNA levels are increased.  
Therefore, it is possible that 1,10 phenanthroline may be protecting the virus from 
degradation during endosome processing, perhaps by interfering with metalloproteases. 
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Figure 3.8.  Fluorescence microscopy images and flow cytometry data for HAEC 
treated with 1,10 phenanthroline followed by AAV2-EGFP transduction.  a. Image 
of HAEC transduced with AAV2-EGFP.  b. Image of HAEC treated with 1,10-
phenanthroline followed by AAV2-EGFP transduction.  c. Forward and side scatter 
results for HAEC transduced with AAV2-EGFP from flow cytometry.  d. Forward and 
side scatter results for HAEC treated with 1,10-phenanthroline followed by AAV2-EGFP 
from flow cytometry.  e. Histogram overlay of fluorescence area for HAEC treated with 
AAV2-EGFP (black) and HAEC treated with 1,10-phenanthroline followed by AAV2-
EGFP (red). 
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3.4.5.2. Ethylenediaminetetraacetic acid (EDTA) 
An alternative metal chelator, ethylenediaminetetraacetic acid   (EDTA), was examined 
and found to have no effect on viral transduction, leading to the conclusion that 1,10-
phenanthroline’s effect on viral enhancement is not general to all metal chelators, 
although it is possible that it may be specific to a subclass of metal chelators such as zinc 
chelators. 
 
Figure 3.9. EDTA luciferase assay dose response results.  EDTA was dissolved at a 
concentration of 100 µM in media, serially diluted in media, and added to HAEC.  24 
hours later, adeno-associated virus was added, followed by luciferase assay after another 
24 hours. 
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3.4.6. Alkylating Agents 
Carboplatin, cisplatin, and melphalan all provided dose-dependent enhancement of 
adeno-associated virus transduction of HAEC.  At high concentrations, both cisplatin and 
melphalan showed a decrease in luminescence signal which was explained by the toxicity 
of these compounds at high concentrations.  Based on these results, it appears that DNA 
alkylation is a mechanism for increased adeno-associated virus transduction. Russel, 
Alexander, and Miller demonstrated that treating cells with radiation or DNA-damaging 
chemicals enhanced adeno-associated virus transduction, and our results corroborate 
those findings.
18, 79, 80
   
3.4.6.1. Carboplatin 
Carboplatin, an alkylating agent, was found to have a dose-dependent enhancement of 
adeno-associated virus activity.  Carboplatin demonstrated a 2.5 fold increase in 
transduction efficiency in primary screening (Appendix Table A4).  Carboplatin 
dissolved in DMSO led to an enhancement of up to 7 fold at high concentrations with an 
EC50 based on all available data of about 50 µM (Figure 3.10a).  When dissolved in 
media and filtered, carboplatin’s enhancement activity was more limited, with a 
maximum enhancement of about 2 fold. (Figure 3.10b).  This discrepancy may be due to 
an effect of DMSO or due to limitations of compound solubility in aqueous solution.   
Although the compound is commonly known to be toxic due to its DNA alkylation 
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activity, no viability changes were observed in a dose-response assay over this range 
(Figure 3.10c, d). 
a) 
  
 
b) 
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c) 
 
d) 
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e) 
 
Figure 3.10.  Carboplatin results.  a) Carboplatin was dissolved at a concentration of 10 
mM in DMSO, serially diluted in DMSO, and added to HAEC cells in media such that 
the final DMSO concentration in each well was 1%.  24 hours later, adeno-associated 
virus was added, followed by luciferase assay after another 24 hours.  b) Carboplatin was 
dissolved at a concentration of 10 mM in media, serially diluted in media, and added to 
HAEC cells in media.  24 hours later, adeno-associated virus was added, followed by 
luciferase assay after another 24 hours.  c) HAEC viability after 48 hours of exposure to 
carboplatin dissolved in DMSO, normalized to DMSO control. d) HAEC viability after 
48 hours of exposure to carboplatin dissolved in media.  e) Luciferase assay results for 
HAEC exposed to carboplatin followed by treatment with AAV2, AAV2/1, or AAV2/9. 
 
HAEC treated with 10 µM  carobplatin were additionally subject to transduction with 
AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow 
cytometry, and BCA assay.  As shown in Table 3.1, the amount of viral DNA was the 
same as the control sample, although viral RNA present was increased by a factor of 1.7.   
The average fluorescence was 20% higher than in the control.  The total protein in the 
well was less than the control.  Figure 3.11 provides corresponding information for 
67 
 
fluorescence microscopy and flow cytometry.  Cells treated with the carboplatin do not 
show a large morphological change as determined by microscopy or by flow cytometry 
(Figure 3.11a,b,c,d).  An overlay of the fluorescence data shows the overall fluorescence 
profile shifting slightly to the right. (Figure 3.11e). 
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Figure 3.11.  Fluorescence microscopy images and flow cytometry data for HAEC 
treated with carboplatin followed by AAV2-EGFP transduction.  a. Image of HAEC 
transduced with AAV2-EGFP.  b. Image of HAEC treated with carboplatin followed by 
AAV2-EGFP transduction.  c. Forward and side scatter results for HAEC transduced with 
AAV2-EGFP from flow cytometry.  d. Forward and side scatter results for HAEC treated 
with carboplatin followed by AAV2-EGFP from flow cytometry.  e. Histogram overlay 
of fluorescence area for HAEC treated with AAV2-EGFP (black) and HAEC treated with 
carboplatin followed by AAV2-EGFP (red). 
 
3.4.6.2. Cisplatin 
Cisplatin, a compound highly related to carboplatin, was also tested and found to be 
beneficial for viral transduction.  Alexander and colleagues previously reported that 
cisplatin facilitates adeno-associated virus transduction.
79
  Cisplatin is a very similar 
compound to carboplatin.  It was evaluated in order to determine if enhancement due to 
carboplatin was due to the bidentate carboxylate group of the carboplatin or due to the 
cis-diammine platinum portion of the molecule which it has in common with cisplatin.  
As shown in Figure 3.12a, cisplatin is also capable of enhancing viral transduction, with 
enhancement of nearly 4-fold at its peak.  However, as shown in Figure 3.12b, toxic 
effects begin to be seen between 10 and 100 uM, limiting cisplatin’s effectiveness. 
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a) 
 
b) 
 
Figure 3.12. Cisplatin results.  a) Cisplatin was dissolved at a concentration of 10 mM 
in media, serially diluted in media, and added to HAEC cells in media.  24 hours later, 
adeno-associated virus was added, followed by luciferase assay after another 24 hours.  
b) Cell viability after 48 hours of exposure to cisplatin. 
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3.4.6.3. Melphalan 
Melphalan is another DNA alkylating agent which caused enhancement in primary 
screening, with the observed enhancement of 2.1 fold.  In subsequent dose-response 
experiments, melphalan was capable of enhancement of up to 5-fold, although at high 
concentrations toxicity was observed (Figure 3.13a,b). 
a) 
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b) 
  
 
c) 
 
 
Figure 3.13.  Melphalan luciferase assay and viability results.  a) Melphalan was 
dissolved at a concentration of 10 mM in DMSO, serially diluted in DMSO, and added to 
HAEC cells in media such that the final DMSO concentration in each well was 1%.  24 
hours later, adeno-associated virus was added, followed by luciferase assay after another 
24 hours. b) Cell viability after 48 hours of exposure to melphalan dissolved in DMSO. c) 
Luciferase assay results for HAEC exposed to melphalan followed by exposure to AAV2, 
AAV2/1, or AAV2/9.   
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HAEC treated with 10 µM  melphalan were additionally subject to transduction with 
AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow 
cytometry, and BCA assay.  As shown in Table 3.1, the amount of viral DNA measured 
in the cell was less than in the 1% DMSO control, whereas viral RNA and fluorescence 
were each increased greater than two-fold (2.7 and 2.6 fold, respectively).  The total 
protein per well as measured by BCA assay increased by 70%.  Figure 3.14 provides 
corresponding information for fluorescence microscopy and flow cytometry.  As 
compared with the 1% DMSO control, the cells treated with melphalan appear to have a 
small highly fluorescent population (Figure 3.14a,b).  Flow cytometry showed no 
morphological changes between cells treated with melphalan and those treated with 
DMSO only (Figure 3.14c,d).  An overlay of the fluorescence data shows that the 
fluorescence profile of the melphalan treated cells is shifted to the right slightly in 
comparison with the 1% DMSO only treated cells (Figure 3.14e).    
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Figure 3.14.  Fluorescence microscopy images and flow cytometry data for HAEC 
treated with melphalan followed by AAV2-EGFP transduction.  a. Image of HAEC 
treated with 1% DMSO followed by AAV2-EGFP.  b. Image of HAEC treated with 
melphalan in 1% DMSO followed by AAV2-EGFP.  c. Forward and side scatter results 
for HAEC treated with 1% DMSO followed by AAV2-EGFP from flow cytometry.  d. 
Forward and side scatter results for HAEC treated with melphalan in 1% DMSO 
followed by AAV2-EGFP from flow cytometry.  e. Histogram overlay of fluorescence 
area for HAEC treated with 1% DMSO (black) and melphalan in 1% DMSO followed by 
HAEC treated with AAV2-EGFP (red). 
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3.4.7. Nucleoside Analogs 
Three of the compounds (5-bromo-2-deoxyuridine, vidarabine, and AZT ) identified in 
primary screening are nucleoside analogs which are incorporated during DNA synthesis.  
Two of the three are often used as anti-viral drugs.  AZT is well-known as a reverse 
transcriptase inhibitor for HIV treatment, and vidarabine is used for several different 
virus types.  The third compound, 5-bromo-2-deoxyuridine, is most often used for 
molecular biology experiments as a way to study DNA synthesis.  It is important to note 
that the engineered AAV2 is a single-stranded DNA virus that is not replication 
competent, and therefore some mechanisms that interfere with viral replication (for 
example, reverse transcriptase inhibition) should not affect this virus.  However, the 
evidence here that these nucleoside analogs enhance AAV2 transduction was initially 
surprising.  However, these results do fit with the findings of previous researchers that 
DNA damage enhances AAV2 transduction.
18, 79, 80
 
Four nucleoside analogs were examined in this study.  Three of the four were 
reproducibly found to be beneficial for viral transduction and were well-tolerated in 
viability assays.  Overall, it appears that the addition of nucleoside analogs assists in the 
viral transduction of adeno-associated virus. 
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3.4.7.1. Azidothymine (AZT) 
Azidothymine (AZT) is a nucleoside analog commonly used as an HIV reverse 
transcriptase inhibitor which demonstrated viral enhancement of 2.2 fold in primary 
screening (Appendix Table A4).  As shown in Figure 3.15, AZT demonstrated at most a 
moderate enhancement in dose-response testing, which may be due to experimental 
artifact (well plate edge effects).  Although AZT did not demonstrate enhancement in 
dose-response studies presented here, in preliminary work it demonstrated enhancement 
of up to 2.5-fold (data not shown), suggesting that limitations of the compound’s stability 
may have led it to be less effective during later experiments.   
 
Figure 3.15. Azidothymine (AZT) luciferase results.  AZT was dissolved at a 
concentration of 10 mM in media, serially diluted in media, and added to HAEC cells in 
media.  24 hours later, adeno-associated virus was added, followed by luciferase assay 
after another 24 hours. 
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3.4.7.2. Adenine 9-beta-d-arabinofuranoside (Vidarabine) 
Adenine 9-beta-d-arabinofuranoside (vidarabine) is a nuceloside analog which 
demonstrated a 2.4 fold increase in viral transduction in primary screening 
(Supplementary Table S3).  In dose-response testing, vidarabine showed enhancement of 
up to three-fold at high concentrations, with an EC50 of about 16 µM (Figure 3.16).   
a) 
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b) 
 
c) 
 
 
Figure 3.16.  Vidarabine luciferase and viability results.  a) Vidarabine was dissolved 
at a concentration of 10 mM in media, serially diluted in media, and added to HAEC cells 
in media.  24 hours later, adeno-associated virus was added, followed by luciferase assay 
after another 24 hours. b) HAEC viability following 48 hours of exposure to vidarabine. 
c) Luciferase assay results for HAEC exposed to vidarabine followed by addition of 
AAV2, AAV2/1, or AAV2/9. 
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HAEC treated with 10 µM  vidarabine were additionally subject to transduction with 
AAV2-EGFP and examined using fluorescence microscopy, PCR, qRT-PCR, flow 
cytometry, and BCA assay.  As shown in Table 3.1, the amount of viral DNA was less 
than in the control sample, although viral RNA present was increased by a factor of 2.8.   
The average fluorescence was 40% higher than in the control.  The total protein in the 
well was less than the control.  Figure 3.17 provides corresponding information for 
fluorescence microscopy and flow cytometry.  Cells treated with the vidarabine do not 
show a large morphological change as determined by microscopy or by flow cytometry 
(Figure 3.17a,b,c,d).  An overlay of the fluorescence data shows the overall fluorescence 
profile shifting slightly to the right. (Figure 3.17e). 
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Figure 3.17.  Fluorescence microscopy images and flow cytometry data for HAEC 
treated with vidarabine followed by AAV2-EGFP transduction.  a. Image of HAEC 
transduced with AAV2-EGFP.  b. Image of HAEC treated with 10 µM  vidarabine 
followed by transduction with AAV2-EGFP.  c. Forward and side scatter results for 
HAEC transduced with AAV2-EGFP from flow cytometry.  d. Forward and side scatter 
results for HAEC treated with 10 µM  vidarabine followed by transduction with  AAV2-
EGFP from flow cytometry.  e. Histogram overlay of fluorescence area for HAEC 
transduced with AAV2-EGFP (black) and 10 µM  vidarabine followed by HAEC treated 
with AAV2-EGFP (red). 
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3.4.7.3. Cytosine arabinofuranoside (Cytarabine) 
Based on the high representation of nucleoside analogs as primary screening hits, a 
related compound, cytarabine (cytosine beta-d-arabinofuranoside), was additionally 
examined.  This compound is a cysteine analog.  Cytarabine was examined as a 
nucleoside analog not identified in primary screening to validate the ability of this class 
of chemicals to provide enhancement.  Cytarabine showed an increase of nearly 4-fold 
enhancement at higher doses, with an EC50 of about 16 µM (Figure 3.18a).   
a)  
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b) 
 
Figure 3.18.  Cytarabine luciferase and viability results.  a) Cytarabine was dissolved 
at a concentration of 10 mM in media, serially diluted in media, and added to HAEC cells 
in media.  24 hours later, adeno-associated virus was added, followed by luciferase assay 
after another 24 hours. b) HAEC viability following 48 hours of exposure to cytosine 
arabinofuranoside. 
3.4.7.4. 5-bromo-2’-deoxyuridine 
5-bromo-2’-deoxyuridine is a  nucleoside analog which was identified as an enhancer at 
the level of 2.6 fold enhancement in primary screening (Appendix Table A4).  In dose-
response testing, 5-bromo-2’-deoxyuridine  showed continuous increase in enhancement 
activity of over 4-fold enhancement at the maximum concentration tested of 100 µM 
(Figure 3.19a).  The EC50 for this compound is above 50 µM. 
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a) 
 
b) 
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c) 
 
Figure 3.19.  5-bromo-2’-deoxyuridine luciferase and viability results.  a) 5-bromo-
2’-deoxyuridine was dissolved at a concentration of 10 mM in media, serially diluted in 
media, and added to HAEC cells in media.  24 hours later, adeno-associated virus was 
added, followed by luciferase assay after another 24 hours. b) HAEC viability following 
48 hours of exposure to 5-bromo-2’-deoxyuridine.  c) Luciferase assay results for HAEC 
treated with 5-bromo-2’-deoxyuridine followed by addition of AAV2, AAV2/1, or 
AAV2/9. 
HAEC treated with 10 µM  5-bromo-2’-deoxyuridine were additionally subject to 
transduction with AAV2-EGFP and examined using fluorescence microscopy, PCR, 
qRT-PCR, flow cytometry, and BCA assay.  As shown in Table 3.1, the amount of viral 
DNA was the less than in the control sample, although viral RNA present was increased 
by over five-fold.   The average fluorescence was more increased more than 2 fold 
compared to control.  The total protein in the well was less than the control.  Figure 3.20 
provides corresponding information for fluorescence microscopy and flow cytometry.  
Cells treated with the 5-bromo-2’-deoxyuridine do not show a large morphological 
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change as determined by microscopy or by flow cytometry (Figure 3.20a,b,c,d).  An 
overlay of the fluorescence data shows more cells exhibiting fluorescence at the very 
high end of the spectrum. (Figure 3.20e). 
 
Figure 3.20.  Fluorescence microscopy images and flow cytometry data for HAEC 
treated with 5-bromo-2’-deoxyuridine followed by AAV2-EGFP transduction.  a. 
Image of HAEC transduced with AAV2-EGFP.  b. Image of HAEC treated with 10 µM  
5-bromo-2’-deoxyuridine followed by transduction with AAV2-EGFP.  c. Forward and 
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side scatter results for HAEC transduced with AAV2-EGFP from flow cytometry.  d. 
Forward and side scatter results for HAEC treated with 10 µM  5-bromo-2’-deoxyuridine 
followed by transduction with  AAV2-EGFP from flow cytometry.  e. Histogram overlay 
of fluorescence area for HAEC transduced with AAV2-EGFP (black) and 10 µM  5-
bromo-2’-deoxyuridine followed by HAEC treated with AAV2-EGFP (red). 
 
3.4.8. Cell Cycle Arrestors 
1,10-phenanthroline, although cytotoxic, has been shown to increase transcription and 
activity of p53.
78
  p53 serves many antitumorigenic roles within the cell, one of which is 
to temporarily arrest the cell cycle in the G1 phase.
81
  Daidzein, which also halts 
progression of the cell cycle past G1, is another chemical which enhanced transduction in 
the compound screen.  Previous reports have shown that the S-phase of the cell cycle is 
more permissive to viral transduction, so it is interesting that these compounds arrest the 
cell cycle in G1 rather than in S-phase. 
The mechanism of action of these compounds for enhancement of viral transduction may 
therefore be unrelated to their cell cycle arresting activity, especially in light of the 
minimal enhancement activity demonstrated by NU 2058. 
3.4.8.1. NU 2058 
NU 2058 inhibits cyclin-dependent kinase 1 and cyclin-dependent kinase 2.
82
  It was 
examined in order to evaluate the ability of cell cycle arrestors to enhance viral 
transduction, as inhibition of these kinases restricts the cell’s ability to move from G1 
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into S phase.  NU 2058 showed limited enhancement in dose-response testing. (Figure 
3.21). 
 
 
Figure 3.21: NU 2058 luciferase assay results.  NU2058 was dissolved at a 
concentration of 10 mM in 100% DMSO, serially diluted in media, and added to HAEC 
cells in media.  24 hours later, adeno-associated virus was added, followed by luciferase 
assay after another 24 hours. 
3.5. Discussion 
Over two thousand compounds were tested for enhancement of adeno-associated viral 
transduction, and 20 (0.9%) were identified as hits with enhancement of two-fold or 
greater.  These compounds represented many different types of pharmacologically active 
agents.  Although a variety of families of compounds were tested, several classes of 
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molecules stood out as being overrepresented in the list of primary screening hits, 
including EGFR tyrosine kinase inhibitors, antioxidants, nucleoside analogs, and 
alkylating agents. 
EGFR tyrosine kinase inhibitors were not studied in detail, although the presence of 
several Tyrphostin compounds in screening results did agree with previous data that these 
compounds enhance AAV2 transduction. 
Several primary screening hits have antioxidant activity, including the top enhancer, 
ellagic acid.  However, dose-response studies with other compounds including caffeic 
acid phenethyl ester, ascorbic acid, and N-acetyl cysteine, failed to show a smilar level of 
benefit.  A detailed investigation of ellagic acid effects on the cell-virus interaction found 
that while viral DNA levels were unchanged, mRNA levels and reporter gene expression 
levels were very high.  However, levels of cellular mRNA and total protein also appeared 
to increase. 
1,10-phenanthroline, the second highest hit in primary screening, demonstrated 
enhancement of viral transduction that was not replicated with a second metal chelator 
tested, EDTA.  This compound was the only chemical tested which resulted in an 
increase in viral DNA as measured by quantitative real time PCR, indicating that its 
mechanism is unique amongst the compounds investigated.  However, as multiple viral 
pseudotypes which bind to different cell surface receptors all were enhanced by the 
addition of 1,10-phenanthroline, the mechanism is not related to increased binding of the 
virus to the cell surface. 
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DNA damaging agents including nucleoside analogs and alkylating agents facilitated 
AAV2 transduction, and specifically led to an increase in mRNA levels.  This is 
consistent with previous research indicating that damaging cellular DNA enhances AAV 
transduction. .
18, 79, 80
 
Cell cycle arrestors may be beneficial for adeno-associated viral transduction, but the one 
compound tested that was not identified in primary screening (NU 2058) did not enhance 
transduction. 
The results from this study demonstrated the feasibility of the high throughput screening 
approach to identifying small molecule enhancers of AAV2.  Furthermore, a small set of 
strong enhancers of AAV2 has been identified and some mechanistic insight was gained.  
These enhancers and their respective mechanisms can serve as a basis for further study. 
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Chapter 4 
4. Conclusions and Future Work 
4.1. Conclusions 
Gene therapy holds the potential to allow a new set of diseases to be prevented, treated, 
or cured.  Following successful delivery and expression of the target gene, cells produce 
the therapy themselves, allowing targeted, novel treatments that were impossible in the 
past. 
While gene therapy holds such promise, there is a lot of research required to make this 
dream a reality.  A major challenge for all gene therapy treatments is to identify a vector 
that will be safe and effective. 
In many ways, adeno-associated virus is an ideal vector for gene delivery.  This vector is 
safe, causing no known human disease and evoking little to no immune response. The 
ability to select from a variety of natural serotypes and/or engineer new serotypes allows 
it to be targeted to specific organs and disease types.  The most pressing drawback to the 
use of this virus is limited efficacy.   
In an effort to address this issue, we have used high throughput screening to identify 
enhancers of AAV2 transduction of human endothelium.  In the first screen, we used 
siRNA knockdown of 5,520 human gene targets to identify siRNA enhancers.  In the 
90 
 
second screen, we treated HAEC with 2,320 chemical compounds to identify small 
molecule enhancers. 
The siRNA high throughput screen identified 10 siRNA sequence hits.  One of the top 
hits, the CLIC2(C) siRNA sequence, enhanced transduction due to an off-target effect 
unrelated to a decrease in CLIC2 mRNA.  The action of this siRNA was found to be 
related to a hexamer seed region [5’-U2GUUUC7-3’] which was shared with several other 
top siRNA sequence hits.   
Although the specific mechanism by which the CLIC2(C) sequence acts remains 
unknown, transcription profiling implicated the interferon pathway.  Knockdown of the 
interferon (alpha, beta, omega) receptor 2 was additionally shown to benefit transduction, 
and addition of interferon alpha or beta was shown to hamper transduction.  These results 
have potential implications for cancer gene therapy, as one clinical strategy being studied 
uses AAV2 to deliver interferon-β to cancer cells.  Although these studies have shown 
positive results, there is a possibility that repeat administration of the vector could be 
inhibited by the interferon transgene. 
The chemical compound screen identified individual chemical hits as well as several 
categories of enhancing compounds.  Specifically, ellagic acid, 1,10-phenanthroline, 
alkylating agents, nucleoside analogs, and EGFR protein tyrosine kinase inhibitors stood 
out.  Although antioxidants initially appeared to benefit viral transduction, additional 
compounds which were tested such as ascorbic acid, n-acetyl cysteine, and curcumin all 
failed to demonstrate a gene delivery benefit.  Additional chemical functions such as cell 
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cycle arrest and metal chelation did not appear to have strong enhancement effects.  
EGFR protein tyrosine kinase inhibitors were not examined in great detail since their 
mechanism of enhancing AAV has already been explored by other researchers.
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In primary screening, ellagic acid provided the strongest enhancement to AAV2 
transduction, with nearly 8-fold stronger luminescence signal than control.  Within the 
dose range studied, ellagic acid showed a dose-dependent increase in transduction 
efficiency with increasing dose.  Detailed studies showed that the ellagic acid benefit can 
be measured beginning with strongly increased mRNA levels, although viral DNA levels 
are unchanged.  However, there is some evidence that this may be due to a global 
mechanism of increased mRNA transcription, and must be studied further to determine 
whether this increase is specific to the AAV2 vector. 
1,10-phenanthroline was the second-strongest hit identified in primary screening, with 
over 6-fold enhancement of signal.  This enhancement comes downstream of viral 
attachment to cell surface receptors, but increased viral DNA signal is observed.  This 
suggests that the effect of 1,10-phenanthroline comes at either the endosomal 
processing/transport stage or the viral second-strand DNA synthesis stage of the viral 
transduction process.  Given the metalloprotease inhibitor characteristics of this 
compound, one possibility is that it protects the virus from degradation by 
metalloproteases during endosomal processing. 
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Both alkylating agents and nucleoside analogs were successful in enhancing AAV2 
transduction.  Both of these categories of chemicals damage DNA, and the cellular DNA 
repair mechanisms may be implicated in assisting viral transduction.
18, 79, 80
 
4.2. Future Work 
4.2.1. siRNA Mechanism 
Future work is needed to determine the significance of the hexamer seed region identified 
in siRNA screening.  A variety of different techniques can be used in an effort to tackle 
this problem. 
First, as the field of miRNA research develops and more information is added to 
bioinformatic databases, the importance of this specific hexamer sequence may become 
clearer.  Specifically, monitoring of the microRNA databse at www.mirdb.org would be 
beneficial.
83, 84
 
Further transcriptional profiling with more controls added would allow finer tuning of 
microarray results.  Specifically, a comparison could include active CLIC sequence A or 
B, active CLIC2 sequence C, and a mutated sequence with the mutation outside the 
hexamer seed region.  Transcripts which are similar for the active CLIC2 sequence but 
not the mutant are then known to be related to CLIC2 knockdown rather than to the 
hexamer seed region.  Transcripts which are similar for the two sequences containing the 
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hexamer seed region but that are lacking in CLIC2 sequence A or B would be the most 
critical to investigate.   
Additionally, mechanistic studies similar to what was performed for the chemical 
compounds, including quantification of viral RNA and DNA, could be carried out for top 
siRNA hits in order to provide a better understanding of where the siRNA enhances the 
viral transduction pathway. 
4.2.2. Examination of Additional Compound Hits 
For this work, we selected a subset of screening hits to focus on.  Of the screening hits, 
there remain several compounds which were not prioritized in this work, but which could 
yield interesting results.  Specifically, SB 202190 (4-(4-Fluorophenyl)-2-(4-
hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) and DAPH (4,5-Dianilinophthalimide) are 
ripe candidates for investigation.  SB 202190 is a p38 MAP kinase inhibitor and had 3.5 
fold enhancement in primary screening, which was the fourth highest hit.  DAPH is a 
protein tyrosine kinase inhibitor and had three-fold enhancement in primary screening, 
making it the fifth highest hit.  The p38 MAP kinase inhibition mechanism may prevent 
the cell from producing immune-related cell signals.  The protein tyrosine kinase 
inhibition of DAPH may or may not affect adeno-associated virus via the same 
mechanism as the EGFR protein tyrosine kinase inhibition of the Tyrphostin compounds. 
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4.2.3. Detailed Mechanism for Chemical Enhancement 
Although the DNA damaging agents and EGFR protein tyrosine kinase inhibitors have 
been previously investigated by other researchers, we have also identified a few 
chemicals whose enhancement is via an unknown function.  A closer examination of 
these mechanisms may lead to a better understanding of AAV2 biology, ultimately 
resulting in optimized formulations for viral delivery vectors or improved engineering of 
the vector itself. 
Although antioxidant effects were initially suspected to be the cause of ellagic acid 
enhancement, these results were not confirmed by studies involving other antioxidants.  
Ellagic acid appears to enhance viral transduction at a stage prior to or beginning with 
transcription of mRNA.  Also, ellagic acid increases mRNA transcription and protein 
production non-specifically, although the extent to which viral mRNA and protein 
production took place appears to be much higher than the level of increase that we have 
measured.  Initial studies can examine cellular mRNA and protein production to quantify 
how much of the ellagic acid benefit is due to non-specific mechanisms.  Additional 
potential mechanisms for the enhancement of ellagic acid may be related to effects on the 
cell cycle or activation of DNA repair mechanisms in response to DNA intercalation. 
1,10-phenanthroline also enhanced AAV2 transduction via an unknown mechanism, 
although in this case levels of viral DNA were increased as well as transgene mRNA and 
protein levels.  In order to study this in more depth, it will be useful to determine whether 
the increase in DNA is due to an increased ability of the virus to survive the endosome 
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and enter the nucleus, or if it is due to an increase in the second strand synthesis of DNA.  
Known lyosome inhibitors could be added to the cells in order to determine if an increase 
in viral transduction is possible as a result of decreased viral degradation in the 
endosome.  If so, then a combination of 1,10-phenanthroline and the lyosome inhibitor 
could be added to cells.  The combination of the two chemicals would be expected to 
result in little to no additive effect.  In order to determine if the increase is related to 
second strand synthesis of DNA, a DNA synthesis inhibitor with and without the 1,10-
phenanthroline could be added to cells in order to block the second strand synthesis of 
DNA.  Then viral DNA quantities could be measured.  If the viral DNA is the same in 
both cases, then enhancement is likely due to an increase in DNA synthesis.  If the viral 
DNA quantity is different between the two, then enhancement occurs prior to DNA 
synthesis. 
4.2.4. Screening of Additional Compound Libraries 
This study identified several chemical enhancers of adeno-associated virus transduction 
out of a total of 2,320 compounds studied.  However, much larger chemical libraries are 
available for screening.  A much larger data set of chemical enhancers could be generated 
using these libraries, in order to identify a more complete understanding of adeno-
associated virus biology and methods of enhancement. 
Additionally, the primary screen presented here looked at chemicals at a single 
concentration (10 µM  in 0.1% DMSO).  A more complete set of chemical enhancers 
could be generated by examining more than one concentration, as the selected 
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concentration could be toxic for some compounds or not high enough to be effective for 
others. 
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5. Appendix 
Table A1. Presence of hexamer seed region within the 3’-untranslated region. 
Gene Symbol 5'-GAAACA-3' 
IFIT5 no match 
IFI44L hexamer in three locations within 3' UTR 
MX1 no match 
TRIM48 no match 
SLC5A2 no match 
CLIC2 hexamer in three locations within 3' UTR 
OR51E1 no match 
LCK no match 
SLC7A2 hexamer in one location within 3' UTR 
ABCA8 no match 
DRD1 hexamer in one location within 3' UTR 
ZMYND8 hexamer in two locations within 3'UTR 
KALRN no match 
GPR77 no match 
MLL hexamer in one location within 3' UTR 
PIP5K1A no match 
TAS2R13 no match 
ALPI no match 
BACE1 no match 
TAS2R10 not found in database 
CAMKK1 no match 
C8G no match 
ITPKA no match 
GDPD1 hexamer in two locations within 3' UTR 
RYR3 no match 
FLAD1 no match 
PDE5A hexamer in one location within 3' UTR 
RAD50 hexamer in one location within 3' UTR 
VIPR2 no match 
GRPR no match 
LPHN2 no match 
NCOA6 no match 
FZD2 no match 
HGS no match 
GART no match 
PIK3C2A hexamer in one location within 3' UTR 
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Gene Symbol 5'-GAAACA-3' 
CDK16 no match 
GPR126 hexamer in one location within 3' UTR 
FMNL1 no match 
DUSP4 hexamer in two locations within 3' UTR 
PTPRD no match 
GIT2 hexamer in three locations within 3' UTR 
NR4A3 hexamer in two locations within 3' UTR 
ADRBK2 hexamer in one location within 3' UTR 
SENP6 hexamer in two locations within 3' UTR 
DGKD hexamer in two locations within 3' UTR 
NCOA1 hexamer in five locations within 3' UTR 
ADRA2B hexamer in three locations within 3' UTR 
CNKSR1 no match 
CDK18 hexamer in one location within 3' UTR 
TPSAB1 no match 
USP10 no match 
KCNH5 hexamer in one location within 3' UTR 
KREMEN2 hexamer in one location within 3' UTR 
 
   
 
Table A2.   HAEC mRNA transcripts that were up-regulated or down-regulated following delivery of CLIC(C)  
siRNA relative to CLIC(C)-U4A mutant. 
Transcript 
ID 
Gene 
Symbol 
Name RefSeq p-value SAM q-
value 
(%) 
Fold Change 
(Negative Indicates 
CLIC2 down-regulated 
vs mutant) 
8165692  --- --- 0.031631 17.9637 -2.73748 
7902541 IFI44L interferon-induced protein 44-like NM_006820 0.022691 17.9637 -2.00103 
8068713 MX1 myxovirus (influenza virus) 
resistance 1, interferon-inducible 
NM_002462 0.015001 17.9637 -1.86237 
7964640  --- --- 0.017268 17.9637 -1.62343 
7951091  --- --- 0.009011 17.9637 -1.61372 
7959482  --- --- 0.019299 17.9637 -1.57954 
8127987 SNORD50A small nucleolar RNA, C/D box 
50A 
NR_002743 0.015405 17.9637 -1.56698 
7969091  --- --- 0.00999 17.9637 -1.55793 
8140907  --- --- 0.020332 17.9637 -1.53483 
7952339 SNORD14C small nucleolar RNA, C/D box 
14C 
NR_001453 0.018541 17.9637 -1.50519 
7951341  --- --- 0.014682 17.9637 -1.43389 
7911331  --- --- 0.014317 17.9637 -1.40324 
7924463  --- --- 0.014317 17.9637 -1.40324 
7927089  --- --- 0.014317 17.9637 -1.40324 
7945347  --- --- 0.014317 17.9637 -1.40324 
7998115  --- --- 0.014317 17.9637 -1.40324 
8031997  --- --- 0.014317 17.9637 -1.40324 
8102530  --- --- 0.014317 17.9637 -1.40324 
8137668  --- --- 0.014317 17.9637 -1.40324 
7939912 TRIM48 tripartite motif-containing 48 NM_024114 0.005948 17.9637 -1.4031 
8073332  --- --- 0.010579 17.9637 -1.40015 
8173627  --- --- 0.002809 17.9637 -1.3619 
9
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Transcript 
ID 
Gene 
Symbol 
Name RefSeq p-value SAM q-
value 
(%) 
Fold Change 
(Negative Indicates 
CLIC2 down-regulated 
vs mutant) 
8081233  --- --- 0.004376 17.9637 -1.36033 
7982751  --- --- 0.011742 17.9637 -1.35719 
8173156  --- --- 0.012164 17.9637 -1.35029 
8069508 CCDC29 coiled-coil domain containing 29 ENST00000333394 0.004879 17.9637 -1.34807 
8055486  --- --- 0.008705 17.9637 -1.3451 
8168412 LOC554203 alanyl-tRNA synthetase domain 
containing 1 pseudogene  
BC029480 0.011567 17.9637 -1.33906 
8165656  --- --- 0.001565 17.9637 -1.33826 
8065853  --- --- 0.007025 17.9637 -1.33543 
8022761  --- --- 0.010789 17.9637 -1.31968 
7929072 IFIT5 interferon-induced protein with 
tetratricopeptide repeats  
NM_012420 0.012384 17.9637 -1.31614 
7900214  --- --- 0.000955 17.9637 -1.3111 
8081107  --- --- 0.008624 17.9637 -1.31104 
7928821  --- --- 0.010724 17.9637 -1.28762 
8084605  --- --- 0.005136 17.9637 -1.28731 
7896746  --- --- 0.010914 17.9637 -1.28075 
8092594  --- --- 0.011726 20.4893 -1.27162 
8072139  --- --- 0.004583 17.9637 -1.26927 
7942379  --- --- 0.006148 17.9637 -1.25061 
7950003 MRGPRD MAS-related GPR, member D  NM_198923 0.023057 24.8533 1.25216 
7992756  --- --- 0.007131 19.0368 1.25487 
7934731 C1D C1D nuclear receptor co-repressor  NM_006333 0.020163 24.8533 1.25554 
7976806  --- --- 0.014037 22.0738 1.25831 
8131705 RPL23P8 ribosomal protein L23 pseudogene 
8  
NR_026673 0.004311 18.6434 1.25898 
7913801  --- --- 0.003384 18.6434 1.25992 
7959144  --- --- 0.015752 22.0738 1.27117 
7941863  --- --- 0.003355 18.6434 1.27129 
1
0
0
 
   
 
Transcript 
ID 
Gene 
Symbol 
Name RefSeq p-value SAM q-
value 
(%) 
Fold Change 
(Negative Indicates 
CLIC2 down-regulated 
vs mutant) 
8122277  --- --- 0.007724 19.0368 1.27417 
8137131  --- --- 0.009623 20.4893 1.27739 
8060080 OR6B2 olfactory receptor, family 6, 
subfamily B, member 2   
NM_001005853 0.028654 24.8533 1.28917 
8120059  --- --- 0.01944 22.8629 1.29556 
7925031 FLJ30430 hypothetical protein FLJ30430 AK054992 0.000801 17.9637 1.29809 
7932964 C1D C1D nuclear receptor co-repressor NM_006333 0.006937 18.6434 1.302 
8175098 GPR119 G protein-coupled receptor 119  NM_178471 0.000619 17.9637 1.30264 
8150034  --- --- 0.007808 18.6434 1.30586 
7972977  --- --- 0.018187 22.0738 1.32413 
8124510 HIST1H2BL histone cluster 1, H2bl NM_003519 0.035442 24.8533 1.34068 
8019804 ROCK1 Rho-associated, coiled-coil 
containing protein kinase 1  
BC041849 0.027604 24.8533 1.34177 
7980906  --- --- 0.01478 20.4893 1.34784 
8052698 C1D C1D nuclear receptor co-repressor NM_006333 0.005958 18.6434 1.34983 
7921358  --- --- 0.003357 17.9637 1.3693 
8026339 SNRPG small nuclear ribonucleoprotein 
polypeptide G 
NM_003096 0.016268 20.4893 1.42612 
8164006  --- --- 0.041601 24.8533 1.46167 
8062490 SNORA60 small nucleolar RNA, H/ACA box 
60 
NR_002986 0.00077 17.9637 1.46669 
8115679  --- --- 0.045774 24.8533 1.59728 
8129309  --- --- 0.010283 17.9637 1.70123 
7914216 SNORA16A small nucleolar RNA, H/ACA box 
16A 
NR_003035 0.018496 18.6434 1.72586 
 
1
0
1
 
   
 
Table A3. Chemicals purchased from Sigma for screening hit confirmation and follow-up experiments. 
Catalog Number Compound Description 
E2250 Ellagic Acid 
320056 1,10-Phenanthroline monohydrate 
S7067 SB 202190 
D3943 DAPH  
B5002 5-Bromo-2′-deoxyuridine 
T3434 Tyrphostin AG 490 
T4693 Tyrphostin AG 537 
T5193 Tyrphostin AG 698 
C2538 Carboplatin 
C8221 Caffeic acid phenethyl ester 
A5762 Adenine 9-β-D-arabinofuranoside 
W104 WIN 62,577 
A2169 3′-Azido-3′-deoxythymidine  
D7802 Daidzein  
S0693 SB 204741  
M2011 Melphalan 
C1386 Curcumin  
A8199 N-Acetyl-L-cysteine 
C1768 Cytosine β-D-arabinofuranoside  
T7165 Tyrphostin 23 
22040 β-Carotene purum 
N4286 NU20580 
1
0
2
 
   
 
Table A4. Compound screening enhancer hits. 
Compound Name Function Normalized 
Luminescence 
Ellagic acid  Antioxidant, pp60
src
 tyrosine kinase 
inhibitor 
7.9  
1,10-Phenanthroline monohydrate  Metalloprotease inhibitor, metal chelator 6.4  
Tyrphostin AG 698  EGFR protein tyrosine kinase inhibitor 3.7  
4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-
pyridyl)-1H-imidazole  
p38 MAP kinase inhibitor 3.5  
4,5-Dianilinophthalimide  Protein tyrosine kinase inhibitor 3.0  
5-Bromo-2 -deoxyuridine  Nucleoside analog, mutagen 2.6  
Tyrphostin AG 490  JAK-2 protein tyrosine kinase inhibitor,  
EGFR protein tyrosine kinase inhibitor 
2.5  
Carboplatin  Alkylating agent, platinum analog 2.5  
Caffeic acid phenethyl ester  Antioxidant 2.5  
Vidarabine  Nucleoside analog, inhibits viral 
replication 
2.4  
WIN 62,577  Tachykinin receptor NK1 antagonist 2.4  
7,4 -Dihydroxyflavone  Antioxidant 2.3  
3-Azido-3-deoxythymidine  (AZT) Nucleoside analog,  
reverse transcriptase inhibitor 
2.2  
Daidzein  Antioxidant, isoflavone 2.2  
Resveratrol  Antioxidant, flavanoid 2.1  
N-(1-Methyl-1H-5-indolyl)-N′-(3-methyl-5-
isothiazolyl)urea  
Serotonin receptor 5-HT2B antagonist 2.1  
1
0
3
 
   
 
Compound Name Function Normalized 
Luminescence 
7,2 -Dihydroxyflavone  Antioxidant, flavanoid 2.1  
Melphalan  Alkylating agent 2.1  
Tyrphostin AG 537  EGFR protein tyrosine kinase inhibitor 2.1  
8-Bromo-cAMP sodium  Protein kinase A activator 2.0  
1
0
4
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